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NUCLEAR RECEPTOR EXPRESSION AND CHARACTERIZATION OF 
THE MAJOR RETINOIC ACID TARGET GENE IN MELANOMA 
 
 
Linda L. Eastham 
 
 
 
 
     Malignant melanoma is the primary cause of death from all diseases arising 
from the skin and it is one of the most resistant tumors to standard treatment 
options.  The increasing incidence of melanoma and its poor prognosis makes the 
understanding of melanoma cell biology very important.  Melanoma progression 
is a complex, multi-step process, and the molecular events leading to melanoma 
tumor cell proliferation and invasion still need further examination.  This study is 
focused on measuring the expression and activity of two specific genes and their 
protein counterparts that are altered during melanoma progression.  It also 
examines the mechanism through which Vitamin A induces melanoma cell 
differentiation and inhibits tumor cell growth.   
     The first part of this research focused on a family of ligand activated 
transcription factors, the PPARs (Peroxisome Proliferator-Activated Receptors).  I 
examined the expression and activity of PPARs and the effects of PPARα and γ 
agonists on the growth of mouse melanocytes and melanoma cells.  I found 
increased expression of PPARα and γ protein levels in B16 mouse melanoma 
cells compared to mouse melan-a melanocytes.  PPARγ-selective agonists, 
 xvi 
prostaglandin J2, troglitazone and ciglitazone, were able to inhibit growth of both 
melan-a and B16 cells.  The only effective PPARα agonist was leukotriene B4 
and it was only able to inhibit melan-a cell growth.  PPAR transcriptional activity 
was examined by reporter gene activity and I found a correlation between 
activation of the receptor and its ability to inhibit cell growth. 
     The second part of my thesis work examines the expression and function of an 
indirect target gene of atRA stimulation, AKAP12.  This protein functions as a 
scaffold, assembling a multi-protein complex containing enzymes involved in 
regulating the activity of various signaling pathways.  Results show atRA 
treatment of mouse and human melanocytes and melanoma cells increased 
AKAP12 expression, and this change was modulated by the transcription factor 
AP-1.  I found a significant correlation between atRA induction of AKAP12 
mRNA and the ability of atRA to inhibit growth.  Functional studies using 
AKAP12 siRNA to decrease the level of this protein indicate that AKAP12 
contributes to the ability of melanoma cells to invade and grow in an anchorage-
independent manner.    
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        Chapter1: Introduction_______________________ 
 
Melanoma 
 
     Cutaneous malignant melanoma (CMM) is a deadly cancer of the skin.  It 
arises from melanocytes, located in the basal layer of the epidermis.  These cells 
produce the pigment melanin, which is not only responsible for the coloration of 
hair and skin, but has photoprotective qualities enabling it to protect skin cells 
from UV-induced DNA damage.  Melanocytes are derived from cells of the 
neural crest and are also located in tissues such as brain, inner ears, heart and eyes 
(Santiago-Walker, et. al., 2008). 
     The incidence of melanoma worldwide has been rising for the past three 
decades and it is the sixth most diagnosed cancer in the USA (Boyle, 2011; 
www.cancer.org).  This year (2012), it is estimated that 70,250 Americans will be 
diagnosed with melanoma.  Early diagnosis leads to surgical removal of the tumor 
and results in an average 5 year survival rate of 93%.  However, once the 
melanoma has metastasized, there is an extraordinarily poor survival rate with 
<10% of patients surviving after 5 years (Boyle, 2011).  Until recently, the only 
FDA-approved drug for the treatment of malignant melanoma was the alkylating 
agent dacarbazine (DTIC), which only induced complete remission in 5-10% of 
patients.  Combination therapies using nitrosoureas (carmustine, lomustine), 
taxanes (taxol, docetaxol), platinum-associated drugs (cisplatin, carboplatin), IL-2 
and/or IFN-α have also failed (Boyle, 2011; Soengas and Lowe, 2003).  However, 
within the past year, two new therapeutic agents have been shown to inhibit the 
growth of metastatic melanoma and extend patient lifespan.  The first new FDA-
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approved agent is the monoclonal antibody ipilimumab.  It is currently given to 
treat patients with late stage melanoma that has metastasized or cannot be 
removed by surgery.  This antibody binds to cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4).  It plays an important regulatory role in the immune system.    
This immunoglobulin is expressed on the surface of helper T cells and transmits 
an inhibitory signal to T cells, suppressing the immune system’s T cell response.  
The second FDA-approved compound is the BRAF inhibitor PLX4032 
(vemurafenib).  BRAF is a protein kinase that regulates the mitogen-activated 
protein kinase (MAPK) pathway involved in regulating cell proliferation.  This 
drug targets the V600E (valine to glutamate) activating mutation commonly seen 
in this protein.  This class of drugs has been shown to delay the progression of 
advanced melanoma, improving overall patient survival (Guida, et. al., 2012).  
     After melanoma has been diagnosed, tests are done to find out if the melanoma 
cancer cells have spread within the skin or to other parts of the body.  Staging is 
performed to determine how widespread the melanoma has become.  This 
diagnosis takes into account information on tumor thickness (T) (Breslow 
measurement), whether the melanoma has spread to the nearby lymph nodes (N), 
and whether it has metastasized (M) and to which organs it has reached.  A biopsy 
of the tumor is performed and the thickness is measured under a microscope.  The 
Breslow thickness is a major predictor of prognosis in CMM.  The thinner the 
melanoma, the better the prognosis will be (Osborne and Hutchinson, 2001).  
Melanomas less than 1mm in depth have a very small chance of spreading.  As 
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the melanoma becomes thicker, the chance of spreading increases 
(www.cancer.org).  
     Several factors have been identified that play a role in melanoma formation 
and they can be divided into two categories: environmental factors and host 
factors (Boyle, 2011).  Exposure to UV radiation, usually from the sun, is the 
most important environmental risk factor for developing malignant melanoma.  
UV radiation is composed of both UVA (320-400nm) and UVB radiation (280-
320nm).  Although UVA is the major component of UV radiation and can 
penetrate the deepest, it is the UVB fraction that is mainly responsible for the 
development of skin carcinomas (Oikarinen, et. al., 1991; Benjamin, et. al., 
2007).   
     There are also several host factors that are associated with increased risk.  
These include a family history of melanoma, a large number of benign or 
dysplastic nevi, mutations in the CDKN2A (p16INK4a-ARF) gene and variation in 
the melanocortin-1 receptor (MC1R) genotype that leads to increased sensitivity 
to UV radiation (Boyle, 2011; Benjamin, et. al., 2007; Melnikova and Bar-Eli, 
2008). 
     The process of melanoma progression involves the sequential accumulation of 
a series of genetic alterations that drive cellular transformation. The melanoma 
tumor cells evolve through three distinct phases of growth.  In the radial growth 
phase (RGP), the tumor grows laterally, and although cells may invade the 
dermis, they do not form a nodule.  In the vertical growth phase (VGP), the cells 
grow vertically, invading the underlying tissues and forming a true tumor 
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(Hussein, 2004; Vladislova and Bar-Eli, 2008; Bennett, 2008).  In the metastatic 
phase (Met), the transformed cells are able to invade and spread to distant target 
organs such as the lungs, liver, gallbladder, brain and bones.  
     Many signaling pathways also become dysregulated during melanoma 
development.  The most common mutations are those that constitutively activate 
the proteins NRAS and BRAF.  Activating mutations in these proteins are 
mutually exclusive, with approximately 20% of tumors having NRAS mutations 
and 50-70% of tumors having BRAF mutations (Wagner and Fisher, 2005; 
Haluska, et. al., 2006; Benjamin, et. al., 2007; Bennett, 2008; Boyle, 2011).  
These proteins drive the MAPK pathway, which is a crucial pathway involved in 
the regulation of cellular proliferation and differentiation.  The PTEN/PI3K/AKT 
pathway is also altered.  Inactivating mutations in the tumor suppressor PTEN are 
common in melanoma and seem to be prevalent in tumors harboring a BRAF 
mutation (Wagner and Fisher, 2005; Haluska, et. al., 2006; Benjamin, et. al., 
2007; Boyle, 2011).  The β-catenin pathway is also abnormally regulated in 
approximately 30% of melanoma tumors (Haluska, et. al., 2006; Bennett, 2008).   
β-Catenin, complexed with the transcription factors LEF and TCF can upregulate 
c-myc and cyclin D1, suppress apoptosis and upregulate the transcription factor 
MITF, a master regulator of melanocyte linage.  This factor is responsible for 
regulating melanocyte proliferation, differentiation and survival (Wagner and 
Fisher, 2005; Bennett, 2008; Mitra and Fisher, 2009).  In addition, up-regulation 
of the transcription factor NF-κB is also found in melanoma tumors (Bennett, 
2008; Melnikova and Bar-Eli, 2008).  This factor regulates pathways involved in 
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inflammation, cell cycle regulation, apoptosis and oncogenesis.  Constitutive 
activation of NF-κB is found in melanoma and supports cancer cell survival 
because it is involved in reducing the sensitivity of melanoma cells to 
chemotherapeutic drugs.  It is also linked to the constitutive activation of AKT 
(Bennett, 2008; Melnikova and Bar-Eli, 2008).  The transcription factors STAT3 
and STAT5 (signal transducers and activators of transcription), have also been 
shown to respond to oncogenic stimulation by growth factors or non-receptor 
tyrosine kinases.  They are involved in the down-regulation of anti-apoptotic 
genes such as Bcl-XL.  The activity of STAT3 and 5 are often up-regulated in 
melanoma (Melnikova and Bar-Eli, 2008).  In addition, melanomas are usually 
resistant to external inducers of apoptosis, including TNF-α, FasL and TRAIL.  
The intrinsic apoptotic activator APAF-1 is silenced in advanced melanomas 
(Soengas and Lowe, 2003; Bennett, 2008).   
     Migration and metastasis of melanoma cells mimics a physiologic process 
called EMT (epithelial mesenchymal transition).  During this process cells lose 
their cell-cell and cell-matrix connections and acquire the motile, migratory 
properties of mesenchymal cells.  There is also a down-regulation of the cell 
adhesion protein E-cadherin and an upregulation of N-cadherin.  EMT conversion 
confers metastatic and invasive properties to melanoma cells.  The transcription 
factors SNAIL and SLUG contribute to this process.  Over-expression of SNAIL 
suppresses expression of E-cadherin and SLUG activity is essential for melanoma 
metastasis (Haass, et. al., 2005; Bennett, 2008; Girouard and Murphy, 2011).  
This information reveals that there are many pathways that are dysregulated in 
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melanoma, and these altered pathways drive the formidable aggressiveness of this 
cancer.        
      
Vitamin A 
     Vitamin A is a fat-soluble co-factor present in food that is essential for life.    It 
plays an important role as a coenzyme in vital processes that the body needs to 
function normally.  The structure of Vitamin A makes it good molecule for 
trapping light energy.  It is the molecule responsible for transferring light energy 
into a chemical nerve impulse in the eye (Amann, et. al., 2011).  It is also 
important for the regulation of biological activities such as embryogenesis, cell 
growth, differentiation, reproduction, apoptosis, and bone formation. (Niles, 2000; 
Sun and Lotan, 2002; Mamede, et. al., 2011).   
     Physiological metabolites of Vitamin A are collectively known as retinoids.  
Although the most common dietary form of Vitamin A is retinol, there are over 
4000 natural and synthetic molecules that are structurally and/or functionally 
related to this compound.  Vitamin A is only obtained through the diet in the form 
of retinol, retinyl esters, or proVitamin A (β-carotene).  It is found in foods of 
plant origin such as sweet potatoes and carrots as β-carotene and in animal 
products such as liver and eggs as retinyl esters (Amann, et. al., 2011). 
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A.  Retinol                                                   B.  all-trans Retinoic Acid 
 
C.  Beta-Carotene 
 
 
 
Figure 1.1.  Chemical structures of A) retinol, B) all-trans retinoic acid, and C) 
beta-carotene. 
 
     Retinol is either stored in the liver as retinyl esters or circulates in the 
bloodstream complexed with plasma retinol-binding protein (RBP) or 
transthyretin (pre-albumin).  Plasma membrane receptors for the retinol-binding 
protein mediate the cellular uptake of retinol.  After retinol has been taken up by 
the cell, it becomes bound to cellular retinol-binding protein (CRBP).  Retinol is 
first converted to retinal, before being metabolized into all-trans retinoic acid 
(atRA) by a retinal dehydrogenase.  The major physiologically active metabolite 
of retinol, retinoic acid, becomes bound to cellular retinoic acid-binding protein 
(CRAPB).    The CRABP bound retinoic acid is then delivered to the nucleus of 
the cell by CRABPII, where it will bind to and activate the retinoic acid receptor.  
(Niles, 1998).  
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Figure 1.2.  Retinol metabolism in the body.  Retinol is first converted to all-
trans retinaldehyde by alcohol dehydrogenases or short-chain dehydrogenases 
before being converted to all-trans retinoic acid by aldehyde dehydrogenases 
(Perlmann, 2002). 
 
Retinoic Acid Regulated Gene Expression  
     Retinoids exert their effects on biological processes through the regulation of 
gene expression, which is due to the ability of atRA to bind and activate specific 
nuclear receptors.  There are two distinct sub-families of nuclear retinoid 
receptors.  The first are the RARs (retinoic acid receptors) that bind all-trans 
retinoic acid and 9-cis retinoic acid.  The RXRs (retinoid X receptors) bind only 
9-cis retinoic acid.  There are three distinct subtypes of RXRs and RARs (α, β 
and γ), which are encoded by different and highly conserved genes.  
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Figure 1.3.  Functional domains of steroid receptor proteins.  The A/B region is 
the ligand-independent activation domain, the C region is the DNA-binding 
domain, the D region acts as a hinge, while the E/F region contains the ligand 
binding domain. 
 
     The RARs share functional domains common to other members of the steroid 
hormone receptor gene family.  The A/B region located in the N-terminal portion 
functions as a ligand-independent transcriptional activation domain.  The C region 
contains the DNA-binding domain that consists of two zinc-binding, cysteine-rich 
segments.  The D domain acts as a hinge, whereas the E segment acts as a 
dimerization interface for ligand-dependent transcriptional activation.  This region 
is highly conserved between all of the RAR subtypes.  The C-terminal F region is 
different between the RAR subtypes and at the present time its function is not 
known.  However, it is thought that it may bind the coactivator CBP/p300 (Niles, 
1998). 
     Retinoic acid induces phenotypic changes in target cells by inducing the 
transcriptional activity of the nuclear retinoid receptors.  It is the main activator of 
RARs whereas the RXR serves as its common heterodimeric partner.  The RXRs 
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have the ability to also heterodimerize with other nuclear receptors.  These 
include the thyroid hormone receptor (TR), Vitamin D receptor (VDR), PPARs 
(peroxisome-proliferator activated receptors), and numerous orphan receptors.  
The RAR-RXR heterodimer binds to a specific sequence located in the promoter 
region of the DNA called a retinoic acid response element (RARE) with a half site 
sequence similar to AGGTCA.  It is a direct repeat (DR) of half sites with a 
spacer of 2 to 5 nucleotides (DR2-DR5).  In the absence of ligand, the RAR-RXR 
dimer is bound to the RARE, and held inactive by co-repressors, such as SMRT 
(silencing mediator of retinoid and thyroid signaling) and N-CoR (nuclear 
receptor co-repressor).  These co-repressors bind to the non-liganded receptors 
resulting in suppression of basal transcriptional activity.  The ability of atRA to 
bind to the RARs results in destabilization of this complex and a conformational 
change in the receptors that allow for the disassociation of co-repressors and 
binding of co-activators, such as SRC-1 (steroid receptor co-activator 1) and 
CBP/p300.  Consequently, atRA exerts its effects through changing the structure 
of the receptor, which allows for control of distinct molecular events at retinoid-
regulated promoters (Niles, 1998). 
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Figure 1.4  Modulation of RA induced gene activity by the RAR.  The RAR/RXR 
heterodimer mediated the effects of RA.  In the absence of ligand (RA), the 
heterodimer complex is bound to DNA at its retinoic acid response element 
(RARE) and also bound to co-repressors.  This complex induces transcriptional 
repression through histone deacetylation.  Binding of ligand (RA) induces a 
conformational change that leads to binding of co-activators and histone 
acetylation, which induces gene activation.  Hox genes are targets of RA induced 
activity during mammalian embryonic development.  These genes are responsible 
for the determination of the basic structure and orientation of an organism 
(Marletaz , et. al.,2006).      
 
     An important regulatory mechanism that co-activators and co-repressors have 
is that they harbor histone acetylation/deacetylation enzyme activity.  Acetylation 
of lysine residues on nucleosome tails results in the relaxation of the chromatin 
structure, allowing access of transcription factors to DNA and therefore, an 
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increase in transcriptional activity.  Co-activators, such as CBP/p300, contain 
histone acetyl-transferase (HAT) activity while co-repressors recruit enzymes that 
have histone deacetylase (HDAC) activity.  The level of acetylation is controlled 
by these two opposing families of enzymes, and ultimately, the activity of the 
RAR/RXR complex.          
 
Retinoids and Cancer 
     Retinoids have been used as both chemopreventative and chemotherapeutic 
agents for the treatment of many types of cancers.  Studies using Vitamin A-
deficient animals showed that there was a strong connection between deficiency 
and the susceptibility to cancer (Chambon, 1994; Sporn, et. al., 1976).  The 
addition of retinoic acid to the media of various types of cancer cells grown in 
culture was able to significantly reduce proliferation (Niles, 2000; Bushue, et. al., 
2010).  Retinoic acid can induce differentiation in tumor cells such as 
neuroblastoma (Sidell, 1982), melanoma (Wood, et. al., 1990; Fligiel, et. al., 
1992; Jacob, et. al., 1998; Niles, 2003), and promyelocytic leukemia (Breitman, 
et. al., 1980).  Retinoids are able to elicit their effects on malignant cell growth 
through the regulation of cell growth, differentiation, and apoptosis (Lotan, 1995; 
Bushue, et. al., 2010; Mamede, et. al., 2011).  
     There is evidence that demonstrates a connection between cellular 
transformation and altered expression of RARs.  It is believed that the RAR-β2 
receptor is critical for mediating the growth inhibitory effects of retinoids and its 
down-regulation is correlated with the loss of atRA’s ability to inhibit cell growth 
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(Lotan, 1996; Sun, 2004; Pavan, et. al., 2006; Bushue, et. al., 2010).  The 
expression of this receptor is down-regulated in head and neck cancer, melanoma, 
breast, and oral cancers (Lotan, 1995; Fan, et. al., 2010).  The reactivation of 
RAR-β2 expression leads to reacquisition of atRA’s ability to inhibit cell growth 
(Xu, 2007), therefore it has been considered as a tumor suppressor gene.  The 
silencing of RAR-β2 expression is due to epigenetic changes, mainly DNA 
methylation (Virmani, et. al., 2001; Shaw, et. al., 2006).  Current research from 
our laboratory indicates that, while DNA methylation appears to be the 
predominant mechanism for silencing of RAR-β2 expression, there are other 
mechanisms by which this occurs, such as modulating the levels of acetylation of 
histones H3 and H4 (Fan, et. al., 2010).  
 
Retinoids and Melanoma 
     A number of synthetic and natural occurring retinoids are available for the 
treatment of many skin diseases, including skin cancer (Niles 2002).  Several 
studies have shown that retinoids, especially atRA, are able to induce 
differentiation and growth arrest in both mouse and human melanoma cells 
(Jacob, et. al., 1998; Fligiel, et. al., 1992; Huang, et. al., 2002; Niles, 2003).  
These effects can happen through a number of mechanisms.  In B16 mouse 
melanoma cells, atRA inhibits both anchorage-dependent and –independent 
growth through inhibition of cell growth at the G1 phase of the cell cycle (Niles, 
1987).  It also stimulates the production of melanin and induces an increase in 
nerve growth factor receptors on the cell membrane.  Through suppression of the 
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transformed phenotype, retinoids have also been shown to inhibit invasion and 
metastasis in human melanoma cells (Wood, et., al., 1990; Jacob, et. al., 1998).  
     Numerous studies have shown that retinoids have potential in the prevention 
and treatment of many cancers.  The ability of retinoids to inhibit tumor growth 
may be related to changes in specific signaling pathways.  However, the complete 
mechanism by which they exert their effects still remains poorly understood, and 
needs to be studied in greater detail. 
 
PPARs 
     Peroxisome proliferator-activated receptors (PPARs) are a group of ligand-
activated transcription factors and members of the nuclear hormone receptor 
superfamily that include the thyroid, Vitamin D, and retinoid receptors.  There are 
three separate genes that give rise to the different isoforms of PPAR, termed 
PPARα, β/δ, γ.  Due to differential splicing and alternate promoter usage there are 
three isoforms of gamma - γ1, γ2, γ3 (Fajas, et. al., 1998; Desvergne and Wahli, 
1999; Roberts-Thomson, 2000).  Each of the PPAR isoforms has a different tissue 
distribution, function, and to some extent, different ligand specificity.  PPARα is 
expressed primarily in the liver, heart, kidney, skeletal muscle and brown adipose 
tissue.  PPARβ/δ expression is ubiquitous, while PPARγ is primarily found in 
white and brown adipose tissue, large intestine and spleen (Desvergne and Wahli, 
1999). 
     PPARs function as the body’s fatty acid sensors, regulating genes involved in 
lipid and glucose metabolism (Green, 1995; Desvergne and Wahli, 1999; Escher 
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and Wahli, 2000; Berger and Moller, 2002).  Endogenous ligands include 
palmitic, oleic, linoleic, arachidonic fatty acids, as well as the eicosanoids, 
including prostaglandins and leukotriene B4.  The synthetic ligands include the 
fibrate class of compounds used to treat hyperlipidemia and the thiazolidinediones 
that are used to treat type II diabetes (Roberts-Thomson, 2000; Michalik, et. al., 
2004).   
     Upon activation, PPARs form a heterodimer with the retinoid X receptor.  This 
complex binds a specific sequence in the promoter region of target genes called a 
peroxisome proliferator response element (PPRE).  This sequence is a direct 
repeat of a hexameric nucleotide sequence – AGGTCA – separated by one 
nucleotide, called a DR-1.  This sequence is important in determining PPAR/RXR 
binding specificity (Isseman, et. al., 1993; Roberts-Thomson, 2000).  PPRE 
elements have been identified in the regulatory regions of many genes involved in 
carbohydrate and lipid metabolism (Tontonoz, et. al., 1994; Tontonoz, et. al., 
1995, Schoonjans, et. al., 1996; Fajas, et. al., 1997; Kliewer, et. al., 2001).   
     PPAR activation up-regulates genes involved in β and ω fatty acid oxidation, 
such as acyl CoA oxidase and cytochrome P450 isotypes (Tugwood, et. al., 1992; 
Aldridge, et. al., 1995).  These receptors are also the target for the fibrate class of 
drugs used to treat hyperlipidemia (Forman, et. al., 1997; Kliewer, et. al., 2001).  
PPARγ activation is involved in adipocyte differentiation, as well as glucose and 
fatty acid storage (Rosen, et. al., 1999; Rosen and Spiegelman, 2000; Rosen, et. 
al., 2000).  This receptor is the target for the thiazolidinedione drugs that are used 
as insulin sensitizers for the treatment of type II diabetes (Kletzien, et. al., 1992, 
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Rosen and Spiegelman, 2000; Kliewer, et. al., 2001, Rosen and Spiegelman, 
2001).  The specific role of PPARβ/δ is not defined, but emerging evidence 
suggests that it may play a role in other processes, such as promotion of lipid 
accumulation in macrophages (Nagy, et. al., 1998; Tontonoz, et. al., 1998; 
Vosper, et. al., 2001), differentiation of epithelial cells (Rosenfield, et. al., 1999; 
Matsuura, et. al., 1999), keratinocytes (Westergaard, et. al., 2001), adipocytes 
(Bastie, et. al., 1999; Bastie, et. al., 2000; Hasen, et. al., 2000), cholesterol 
homeostasis (Leibowitz, et. al., 2000; Oliver Jr., et. al., 2001), bone metabolism 
(Mano, et. al., 2000), skin wound healing (Michalik, et. al., 2001; Wahli, 2002), 
and embryo implantation and decidualization (Lim, et. al., 1999).  PPARβ/δ can 
be activated by many of the compounds that activate PPARα (Roberts-Thomson, 
2000).  Specific endogenous ligands that activate this receptor remain unknown, 
although there are data to support that the arachadonic acid metabolite, 
prostacyclin, can act as an endogenous ligand for PPARβ/δ (Shao, et. al., 2002; 
Michalik, et. al., 2003).   
     Aberrant expression of PPAR receptors has been found in several types of 
cancers.  These include colon, prostate, lung, skin, breast, and liposarcomas 
(Sarraf, et. al., 1995; Tontonoz, et. al., 1997; Elstner, et. al., 1998; Mueller, et. al., 
1998; Mueller, et. al., 2000; Motomura, et. al., 2000; Thuillier, et. al., 2000; 
Suchanek, et. al., 2002; Gupta, et. al., 2004).  Involvement of PPARα in 
tumorigenesis is thought to be through induction of cell cycle regulatory genes 
such as CDK-1 and 4 and c-myc (Peters, et. al., 1998; Roberts-Thomson, 2000).  
Furthermore, there is evidence to suggest that this receptor is involved in 
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suppression of apoptosis, which also promotes carcinogenesis (Desvergne and 
Wahli, 1999; Roberts-Thomson, 2000).  PPARβ/δ has been found to be over-
expressed in many human and rodent colorectal cancers and the expression of this 
receptor has been shown to be regulated by the adenomatous polyposis coli 
(APC)/β-catenin/TCF-4 pathway (He, et. al., 1999; Gupta, et. al., 2000; Park, et. 
al., 2001).  PPARγ has powerful effects on cellular differentiation and is thought 
to act as a tumor suppressor gene (Sarraf, et. al., 1999; Ikezoe, et. al., 2001).  
Activation of PPARγ causes inhibition of cell growth and promotes differentiation 
in many epithelial derived cancer cell lines (Sarraf, et. al., 1995; Tontonoz, et. al., 
1997; Elstner, et. al., 1998; Mueller, et. al., 1998; Kubota, et. al., 1998; Mueller, 
et. al., 2000; Chang and Szabo, 2000). 
 
AKAP12 
     A kinase anchoring proteins (AKAPs) are a class of structurally diverse but 
functionally similar scaffolding proteins.  They were discovered due to their 
ability to bind the regulatory subunit of Protein Kinase A (PKA) (Rubin, 1994; 
Dell’Aqua and Scott, 1997; Colledge and Scott, 1999; Feliciello, et. al., 2001; 
Carlisle-Michel and Scott, 2002).  The ability of AKAPs to bind PKA allows the 
holoenzyme to be sequestered at specific regions within the cell where it is 
exposed to increased levels of cAMP.  This allows more efficient activation of the 
enzyme and more precise substrate selection.  AKAP proteins are involved in 
assembling multi-protein signaling complexes that function to promote efficient 
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and specific enzyme/substrate reactions in a spatial and temporal manner 
(Gelman, 2002). 
 
 
Figure 1.5.  Organization of the AKAP12 gene.  The generic gene structure of 
mammalian AKAP12 locus.  The arched lines connecting the exons represent the 
splicing of the three mRNAs encoded by the AKAP12 gene (Streb, et., al., 2004). 
 
     Human AKAP12 is also known as AKAP250 or Gravin.  Gravin was identified 
as the target of an autoantibody in patients with myasthenia gravis and targets the 
PKA binding domain of AKAP12 (Nauert, et. al., 1997).  The rodent orthologue 
is termed SSeCKS (Src-Suppressed C Kinase Substrate) and was discovered in rat 
fibroblasts to be down-regulated upon transformation by oncogenic forms of Src 
and Ras (Lin, et. al., 1996).  The hAKAP12 gene is located on chromosome 6q24-
25.2, which is a deletion hotspot in advanced prostate, breast and ovarian cancer 
(Noviello, et. al., 1996; Cooney, et. al., 1996; Tibilette, et. al., 2000; Tibilette, et. 
al., 2001; Gelman, 2002; Abdollahi, et. al., 2003; Gorringe, et. al., 2009).  
Therefore, it is believed that the AKAP12 locus may encode a tumor suppressor 
gene (Lin, et. al., 2000).  The AKAP12 gene is approximately 100kb long and 
contains 6 exons.  There are 3 distinct gene products, AKAP12α, β, and γ, each 
with their own promoter allowing their expression to be independently regulated.  
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AKAP12α is the main isoform and the protein contains a myristoylation sequence 
that can target it to the cell membrane or endoplasmic reticulum.  In addition to 
binding PKA, AKAP12 proteins also have docking sites for many other kinases 
and adaptor molecules.  These include protein kinase C, phosphatase 2B, 
calmodulin, cyclin D and F-actin (Gelman, 2002).  Mechanisms regulating 
AKAP12 function are still being explored. 
 
 
 
Figure 1.6.  Structure of the AKAP12 scaffolding protein.  AKAP12 contains 
several PKC phosphorylation sites (pS) as well as various protein binding 
domains, including protein kinase A (PKA), protein kinase C (PKC), calmodulin 
(CaM), cyclin D, F-actin, and GalTase (β1,4-galactosyltransferase) a 
AKAP 12 
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transmembrane receptor for laminin.  PxxP represents potential SH3 binding sites.  
AKAP12 also encodes several nuclear localization sites (NLS) (Gelman, 2002).    
 
     The over-expression of AKAP12/SSeCKS in NIH3T3 cells causes inhibition 
of cell growth by promoting G1 phase arrest through binding and regulation of 
cyclin D activity (Lin, et. al., 2000; Gelman, 2002).  It also promotes re-
organization of the actin-based cytoskeleton that induces cell flattening (Nelson 
and Gelman 1997; Gelman, et. al., 1998, Gelman, et. al., 2000; Xia and Gelman, 
2002; Cheng, et. al., 2007).  This restructuring seems to be modulated through 
focal adhesion kinase-dependent tyrosine phosphorylation of AKAP12 (Xia and 
Gelman, 2002).  In addition, re-expression of AKAP12 causes a down-regulation 
of proliferative and pro-angiogenic gene expression, such as VEGF (Su, et. al., 
2006; Liu, et. al., 2006), and also inhibits podosome formation and metastatic 
progression in human prostatic cancer (Lin and Gelman, 1997; Xia, et. al., 2001; 
Gao and Gelman, 2006).  Further evidence for the involvement of this protein in 
cancer is provided by the SSeCKS null mice that develop prostatic hyperplasia 
(Akakura, et. al., 2008).   
 
 
     
 
 
 
 
 
 - 21 - 
Bibliography 
 
Abdollahi A, Pisarcik D, Roberts D, Weinstein J, Cairns P, et. al.  Lot1 
(PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, 
is epigenetically regulated in cancer.  (2003) J Biol Chem 278(8):6041-6049. 
 
Akakura S, Huang C, Nelson PJ, Foster B, and Gelman IH.  Loss of the 
SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia.  (2008) Cancer 
Res 68(13):5096-5103. 
 
Aldridge TC, Tugwood JD, and Green S.  Identification and characterization of 
DNA elements implicated in the regulation of CYP4A1 transcription.  (1995) 
Biochem J 306:473-479. 
 
Amann PM, Eichmuller SB, Schmidt J, and Bazhin AV.  Regulation of gene 
expression by retinoids.  (2011) Current Medicinal Chemistry 18:1405-1412. 
 
Bastie C, Holst D, Gaillard D, Jehl-Pietri C, and Grimaldi PA.  Expression of 
peroxisome proliferator-activated receptor PPARδ promotes induction of PPAR 
gamma and adipocyte differentiation in 3T3C2 fibroblasts.  (1999) J Biol Chem 
274:21920-21925. 
 
Bastie C, Luquet S, Holst D, Jehl-Pietri C, and Grimaldi PA.  Alterations of 
peroxisome proliferator-activated receptor δ activity affect fatty acid-controlled 
adipose differentiation.  (2000) J Biol Chem 257:38768-38773. 
 
Benjamin CL, Melnikova VO, and Ananthaswamy HN.  Models and mechanisms 
in malignant melanoma.  (2007) Molecular Mechanisms 46:671-678. 
 
Bennett DC.  How to make a melanoma: what do we know of the primary clonal 
events?  (2008) Pigment Cell Melanoma Res 21:27-38. 
 
Berger J and Moller DE.  The mechanisms of action of PPARs.  (2002) Annu Rev 
Med 53:409-435. 
 
Boyle G.  Therapy for metastatic melanoma: an overview and update.  (2011) 
Expert Rev Anticancer Ther 11(5):725-737. 
 
Boyle GM, Martyn AC, and Parsons PG.  Histone deacetylase inhibitors and 
malignant melanoma.  (2005) Pigment Cell Res 18:160-166. 
 
Breitman TR, Selonick SE, and Collins SJ.  Induction of differentiation of the 
human promyelocytic leukemia cell line (HL-60) by retinoic acid.  (1980) Proc 
Natl Acad Sci USA 77:2936. 
 
 - 22 - 
Bushue N, Jui Y, and Wan Y.  Retinoid pathway and cancer therapeutics.  (2010) 
Advanced Drug Discovery Reviews 62:1285-1298. 
 
Carlisle-Michel JJ and Scott JD.  AKAP mediated signal transduction.  (2002) 
Annu Rev Toxicol 42:235-257.   
 
Chambon P.  The retinoid signaling pathway: molecular and genetic analysis.  
(1994) 5:115. 
 
Chang TH and Szabo E.  Induction of differentiation and apoptosis by ligands of 
peroxisome proliferator-activated receptor γ in non-small cell lung cancer.  (2000) 
Cancer Res 60:1129-1138. 
 
Cheng C, Liu H, Ge H, Qian J, Qin J, et. al.  Essential role of Src-Suppressed C 
Kinase Substrates in endothelial cell adhesion and spreading.  (2007) Biochem 
Biophys Res Commun 358:342-348. 
 
Colledge M and Scott JD. AKAPs: from structure to function.  (1999) Trends Cell 
Biol 9:216-221. 
 
Cooney KA, Wetzel JC, Consolino CM, and Wojno KJ.  Identification and 
characterization of proximal 6q deletions in prostate cancer.  (1996) Cancer Res 
56;4150-4153. 
 
Demary K, Wong L, and Spanjaard RA.  Effects of retinoic acid and sodium 
butyrate on gene expression, histone acetylation and inhibition of proliferation of 
melanoma cells.  (2001) Cancer Lett 163:103-107. 
 
Dell’Acqua ML and Scott JD.  Protein kinase A anchoring.  (1997) Protein kinase 
A anchoring.  (1997) J Biol Chem 272:12881-12884. 
   
Desvernge B and Wahli W.  Peroxisome proliferator-activated receptors, nuclear 
control of metabolism.  (1999) Endocrine Reviews 20(5):649-688. 
 
Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, et. al.  Ligands for 
perosixome proliferator-activated receptor γ and retinoic acid receptor inhibit 
growth and induce apoptosis of human breast cancer cells in vitro and in BNX 
mice.  (1998) PNAS 95(15):8806-8811. 
 
Escher P and Wahli W.  Peroxisome proliferator-activated receptors: insight into 
multiple cellular functions.  (2000) Mutat Res 448:121-138. 
 
Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, et. al.  The 
organization, promoter analysis, and expression of the human PPARγ gene.  
(1997) J Biol Chem 272(30):18779-18789. 
  
 - 23 - 
Fajas L, Fruchart J, and Auwerx J.  PPAR gamma 3 RNA: A distinct PPAR 
gamma mRNA subtype transcribed from an independent promoter.  (1998) J Biol 
Chem 438:55-60. 
 
Fan J, Eastham L, Varney ME, Hall A, Adkins NL, et. al.  Silencing and re-
expression of retinoic acid receptor beta2 in human melanoma.  (2010) Pigment 
Cell Melanoma Res 23:419-429. 
 
Fligiel SEG, Inman DR, Talwar HS, Fisher GJ, Vorhees JJ, et. al.  Modulation of 
growth in normal and malignant melanocytic cells by all-trans retinoic acid.  
(1992) J Cutan Pathol 19:27-33. 
 
Feliciello A, Gottesman ME, and Avvedimento EV.  The biological functions of 
A-kinase anchor proteins.  (2001) J Mol Biol 308:99-114. 
 
Forman BM, Chen J, and Evans RM.  Hypolipidemic drugs, polyunsaturated fatty 
acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors 
alpha and delta.  (1997) Proc Natl Acad Sci USA 94:4312-4317. 
 
Gao L, and Gelman IH.  SSeCKs/Gravin/AKAP12 metastasis suppressor inhibits 
podosome formation via RhoA- and Cdc42-dependent pathways.  (2006) Mol 
Cancer Res, March 4(3):151-158. 
 
Gelman IH, Lee K, Tombler E, Gordon R, and Lin X.  Control of cytoskeletal 
architecture by the Src-Suppressed C Kinase Substrate, SSeCKS.  (1998) Cell 
Motil Cytoskeleton 41:1-17. 
 
Gelman IH, Tombler E, and Vargas Jr. J.  A role for SSeCKS, a major protein 
kinase C substrate with tumour suppressor activity, in cytoskeletal architecture, 
formation of migratory processes, and cell migration during embryogenesis.  
(2000) The Histochemical Journal 32:13-26. 
 
Gelman IH.  The role of SSeCKS/Gravin/AKAP12 scaffolding proteins in the 
spaciotemporal control of signaling  pathways in oncogenesis and development.  
(2002) Frontiers in Bioscience 7:1782-1797. 
 
Girouard SD and Murphy GF.  Melanoma stem cells: not rare, but well done.  
(2011) Laboratory Investigation 91:647-664. 
 
Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, et. al.  Are 
there any more tumor suppressor genes?  A new perspective using ultra high-
resolution copy number and loss of heterozygosity analysis.  (2009) Genes 
Chromosomes Cancer 48(10):931-942. 
 
Green S.  PPAR a mediator of peroxisome proliferator action.  (1995) 333:101-
109. 
 - 24 - 
 
Guida M, Pisonte S, and Colucci G.  Metastatic melanoma: the new era of target 
therapy.  (2012) Expert Opin Ther Targets, 23 March (Epub ahead of print).  
 
Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, et. al. Prostacyclin-
mediated activation of peroxisome proliferator-activated receptor δ in colorectal 
cancer.  (2000) Proc Natl Acad Sci USA 97:13275-13280. 
 
Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, et. al.  Activation of nuclear 
receptor peroxisome proliferator-activated receptor-δ accelerates intestinal 
adenoma growth.  (2004) Nature Medicine 10:245-247. 
 
Haass NK, Smalley KSM, Li L, and Herlyn M.  Adhesion, migration and 
communication in melanocytes and melanoma.  (2005) Pigment Cell Res 18:150-
159. 
 
Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, et. al.  Genetic alterations in 
signaling pathways in melanoma.  (2006) Clin Cancer Res 12(7):2301s-2307s. 
 
Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, et. al.  Peroxisome 
proliferator-activated receptor δ (PPARδ)-mediated regulation of preadipocyte 
proliferation and gene expression is dependent on cAMP signaling.  (2000) J Biol 
Chem 276:3175-3182. 
 
He TC, Chan TA, Vogelstein B, and Kinzler KW.  PPAR delta is an PAC-
regulated target of nonsteroidal anti-inflammatory drugs.  (1999) Cell 99:335-345. 
 
Huang Y, Boskovic G, and Niles RM.  Retinoic acid-induced AP-1 transcriptional 
activity regulates B16 mouse melanoma growth inhibition and differentiation.  
(2002) 194:162-170. 
 
Hussein MR.  Genetic pathways to melanoma tumorigenesis.  (2004) J Clin 
Pathol 797-801. 
 
Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, et. al.  Mutational 
analysis of the peroxisome proliferator-activated receptor γ gene in human 
malignancies.  (2001) Cancer Research 61:5307-5310. 
 
Issemann J, Prince R, Tugwook J, and Green S.  The retinoid X receptor enhances 
the function of the peroxisome proliferator-activated receptor.  (1993) Biochime 
75:251-256. 
 
Jacob K, Wach F, Holzapfel U, Hein R, Lengyei E, et. al.  In vitro modulation of 
human melanoma cell invasion and proliferation by all-trans retinoic acid.  (1998) 
Melanoma Res 8(3):211-219. 
 
 - 25 - 
Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, et. al.  Antitumor 
effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis 
retinoic acid in human malignant melanoma.  (2007) Mol Cancer Ther 6:70-81. 
 
Kletzien RF, Clarke SD, and Ulrich RG.  Enhancement of adipocyte 
differentiation by an insulin sensitizing agent.  (1992) Mol Pharmacol 41:393-
398. 
 
Kliewer SA, Xu HE, Lambert MH, and Wilson TM.  Peroxisome proliferator-
activated receptors: From genes to physiology.  (2001) Recent Prog Horm Res 
56:239-261. 
 
Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, et. al.  Ligand for 
peroxisome proliferator-activated receptor gamma (troglitazone) has potent anti-
tumor effect against human prostate cancer both in vitro and in vivo.  (1998) 
Cancer Res 58:3344-3352.  
 
Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, et. al.  
Activation of PPARδ alters lipid metabolism in db/db mice.  (2000) FEBS Lett 
473:333-336. 
 
Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, et. al.  Cyclo-oxygenase-2-
derived prostacyclin mediates embryo implantation in the mouse via PPARδ.  
(1999) Genes Dev 13:1561-1574. 
 
Lin X, Tombler E, Nelson PJ, Ross M, and Gelman IH.  A novel src- and ras-
suppressed protein kinase C substrate associated with cytoskeletal architecture.  
(1996) J Biol Chem 271(45):28430-28438. 
 
Lin X, and Gelman IH.  Re-expression of the major protein kinase C substrate, 
SSeCKS, suppresses v-src-induced morphological transformation and 
tumorigenesis.  (1997) Cancer Res 57:2304-2312. 
 
Lin X, Nelson P, and Gelman IH.  SSeCKS, a major protein kinase C substrate 
with tumor suppressor activity, regulates G1→S progression by controlling the 
expression and cellular compartmentalization of cyclin D.  (2000) Mol Cell Biol 
20(19):7259-7272. 
 
Liu Y, Gao L, and Gelman IH.  SSeCKS/Gravin/AKAP12 attenuates expression 
of proliferative and angiogenic genes during suppression of v-src-induced 
oncogenesis.  (2006) BMC Cancer 6(105):1-12. 
 
Lotan R.  Retinoids and apoptosis: implications for cancer chemoprevention and 
therapy.  (1995) J Natl Cancer Inst 87:1655-1657. 
 
 - 26 - 
Lotan R.  Retinoids and their receptors in modulation of differentiatin, 
development, and prevention of head and neck cancers.  (1996) Anticancer Res 
16:2415-2419. 
 
Mamede AC, Tavares SD, Abrantes AM, Trindade J, Maia JM, et. al.  The role of 
vitamins in cancer.  (2011) 63(4):479-494. 
 
Mano H, et. al.  Cloning and function of rabbit peroxisome proliferator-activated 
receptor β/δ in mature osteoclasts.  (2000) J Biol Chem 275:8126-8132. 
 
Marletaz F, Holland LZ, Laudet V, and Schubert M.  Retinoic acid signaling and 
the evolution of chordates.  (2006) Int J Biol Sci 2(2):38-47. 
 
Matsuura H, Adachi H, Smart RC, Xu X, Arata J, et. al.  Correlation between 
expression of peroxisome proliferator-activated receptor β and squamous 
differentiation in epidermal and tracheobronchial epithelial cells.  (1999) Mol Cell 
Endocrinol 147:85-92. 
 
Melnikova VO and Bar-Eli M.  Transcriptional control of the melanoma 
malignant phenotype.  (2008) Cancer Biology & Therapy 7(7):997-1003. 
 
Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, et. al.  Impared skin 
wound healing in peroxisome proliferator-activated receptor (PPAR)α and 
PPARβ mutant mice.  (2001) J Cell Biol 154:799-814. 
 
Michalik L, Desvergne B, and Wahli W.  Peroxisome proliferator-activated 
receptors β/δ: emerging roles for a previously neglected third family member.  
(2003) Current Opinion in Lipidology 14:129-135. 
 
Michalik L, Desvergne B, and Wahli W.  Peroxisome proliferator-activated 
receptors and cancers: complex stories.  (2004) Nature Reviews 4:61-70.   
 
Mitra D and Fisher DE.  Transcriptioal regulation in melanoma.  (2009) Hematol 
Oncol Clin N Am 23:447-465. 
 
Motomura W, Okumura T, Takahashi N, Obara T, and Kohgo Y.  Activation of 
peroxisome-proliferator activated receptor gamma by troglitazone inhibits cell 
growth through the increase of p27KiP1 in human pancreatic carcinoma cells.  
(2000) Cancer Res 60(19):5558-5564. 
 
Mouret S, Forestier A, and Douki T.  The specificity of UVA-induced DNA 
damage in human melanocytes.  (2012) Photochem Photobiol Sci 11(1):155-162. 
 
Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, et. al.  Terminal 
differentiation of human breast cancer through PPARγ.  (1998) Molecular Cell 
1:465-470. 
 - 27 - 
 
Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, et. al.  Effects of ligand 
activation of peroxisome proliferator-activated receptor γ in human prostate 
cancer. (2000) PNAS 97(20):10990-10995. 
 
Nagy L, Tontonoz P, Alvarez JG, Chen H, and Evans RM.  Oxidized LDL 
regulates macrophage gene cell expression through ligand activation of PPAR 
gamma.  (1998) Cell 93:241-252. 
 
Nauert JB, Klauck TM, Langeberg LK, and Scott JD.  Gravin, an autoantigen 
recognized by serum from myasthenia gravis patients is a kinase scaffold protein.  
(1997) Curr Biol 7(1):52-62. 
 
Nelson PJ and Gelman IH.  Cell-cycle regulated expression and serine 
phosphorylation of the myristylated protein kinase C substrate, SSeCKS: 
correlation with culture confluency, cell cycle phase and serum response.  (1997) 
Mol Cell Biochem 175: 233-241. 
 
Niles RM.  (1987) InVitro 23:803-804. 
 
Niles RM.  Chapter 1:  Control of retinoid nuclear receptor function and 
expression.  (1998) Subcellular Biochemistry 30:3-20. 
 
Niles RM.  Recent advances in the use of Vitamin A (Retinoids) in the prevention 
of cancer.  (2000) Nutrition 16:1084-1090. 
 
Niles RM.  The use of retinoids in the prevention and treatment of skin cancer.  
(2002) 3(3):299-303. 
 
Niles RM.  Vitamin A (Retinoids) regulation of mouse melanoma growth and 
differentiation.  (2003) American Society for Nutritional Sciences 282S-286S. 
 
Noviello C, Courjal F, and Theillet C.  Loss of heterozygosity on the long arm of 
chromosome 6 in breast cancer: possibly four regions of deletion.  (1996) Clin 
Cancer Res 2(9):1601-1606. 
 
Oikarinen A, Peltonen J, and Kallioinen M.  Ultraviolet radiation in skin aging 
and carcinogenesis: the role of retinoids for treatment and prevention.  (1991) 
Annals of Medicine 23:497-505. 
 
Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, et. al. A selective 
peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol 
transport.  (2001) Proc Natl Acad Sci USA 98:5306-5311. 
 
Osborne JE and Hutchinson PE.  Clinical correlates of Breslow thickness of 
malignant melanoma.  (2001) 144(3):476-483. 
 - 28 - 
 
Park BH, Vogelstein B, and Kinzler KW.  Genetic disruption of PPARδ decreases 
the tumorigenicity of human colon cancer cells.  (2001) PNAS 98(5):2598-2603. 
 
Pavan B, Biondi C, and Dalpiaz A.  Nuclear retinoic acid receptor beta as a tool in 
chemoprevention trials.  (2006) Curr Med Chem 13:3553-3563. 
 
Perlmann T.  Retinoid metabolism: a balancing act.  (2002) Nature Genetics 31:7-
8. 
 
Peters JM, Aoyama T, Cattley RC, Nobumitsu U, Hashimoto T, et. al.  Role of 
peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in 
mouse liver.  (1998) Carcinogenesis 19:1989-1984. 
 
Roberts-Thomson SJ.  Peroxisome proliferator-activated receptors in 
tumorigenesis: Targets of tumor promotion and treatment.  (2000) 78:436-441. 
 
Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, et. al.  PPARγ is required for 
the differentiation of adipose tissue in vivo and in vitro.  (1999) Mol Cell 4:611-
617. 
 
Rosen ED and Spiegelman BM.  Peroxisome proliferator-activated receptor γ 
ligands and atherosclerosis: ending the heartache.  (2000) J Clin Invest 106:629-
631. 
 
Rosen ED, Walkey CJ, Puigserver P, and Spiegelman BM.  Transcriptional 
regulation of adipogenesis.  (2000) Genes Dev 14:1293-1307. 
 
Rosen ED and Spiegelman BM.  PPARγ: a nuclear regulator of metabolism, 
differentiation, and cell growth.  (2001) J Biol Chem 276(41):37731-37734. 
 
Rosenfield RL, Kentsis A, Deplewski D, and Ciletti N.  Rat preputial sebocyte 
differentiation involves peroxisome proliferator-activated receptors.  (1999) J 
Invest 112:226-232. 
 
Rubin CS.  A kinase anchor proteins and the intracellular targeting of signals 
carried by cAMP.  (1994) Biochem Biophys Acta 1224:467-479. 
 
Santiago-Walker A, Li L, Hass NK, and Herlyn M.  Melanocytes: from 
morphology to application.  (2009) Skin Pharmacol Physiol 22:114-121. 
 
Sarraf P, Mueller E, et. al.  Differentiation and reversal of malignant changes in 
colon cancer through PPARγ.  (1995) Nature Medicine 4(9):1046-1052. 
 
 - 29 - 
Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, et. al.  Loss-of-function 
mutations in PPARγ associated with human colon cancer.  (1999) Mol Cell 3:799-
804. 
 
Satyamoorthy K, Meier F, Hsu MY, Berking C, and Herlyn M.  Human 
xenografts, human skin and skin reconstructs for studies in melanoma 
development and progression.  (1999) Cancer and Metastasis Reviews 18:401-
405. 
 
Schoonjans K, Peinado-Onsurbe J, Lefebure AM, Heyman RA, Briggs M, et. al.  
PPAR alpha and PPAR gamma activators direct a distinct tissue-specific 
transcriptional response via a PPRE in the lipoprotein lipase gene.  (1996) EMBO 
J 15:5336-5348. 
 
Shao J, Sheng H, and DuBois RN.  Peroxisome proliferator-activated receptors 
modulate K-Ras-mediated transformation of intestinal epithelial cells.  (2002) 
Cancer Res 62:3282-3288. 
 
Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, et. al. Promoter 
methylation of p16, RAR beta, E-cadherin, cyclin A1, and cytoglobin in oral 
cancer: quantitative evaluation using pyrosequencing.  (2006) Br J Cancer 
94:561-568. 
 
Sidel N.  Retinoic acid-induced growth inhibition and morphologic differentiation 
of human neuroblastoma in vitro.  (1982) J Natl Cancer Inst 68:589. 
 
Soengas MS and Lowe SW.  Apoptosis and melanoma chemoresistance.  (2003) 
Oncogene 22:3138-3151. 
 
Sporn MB, Dunlop NM, Newton DL, and Smith JM.  Prevention of chemical 
carcinogenesis by Vitamin A and its synthetic analogs (retinoids).  (1976) Fed 
Proc 35:1332. 
 
Streb JW, Kitchen CM, Gelman IH, and Miano JM.  Multiple promoters direct 
expression of three AKAP12 isoforms with distinct subcellular and tissue 
distribution profiles.  (2004) J Biol Chem 279(53):56014-56023. 
 
Su B, Zheng, Vaughan MM, Bu Y, and Gelman IH.  SSeCKS metastasis-
suppressing activity in MatLyLu prostate cancer cells correlates with vascular 
endothelial growth factor inhibition.  (2006) Cancer Res 66(11):5599-5607. 
 
Suchanek KM, May FJ, Robinson JA, Lee WJ, Holman NA, et. al.  Peroxisome 
proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 
and MDA-MB-231.  (2002) Mol Carcinog 34(4):165-171. 
 
 - 30 - 
Sun SY and Lotan R.  Retinoids and their receptors in cancer development.  
(2002)  Critical Rev Oncol Hematol 41:41-55. 
 
Sun SY.  Retinoic acid receptor beta and colon cancer.  (2004) Cancer Biol Ther 
3:87-88. 
 
Thuillier P, Anchiraico GJ, Nickel KP, Maldre RE, Gimenez-Conti I, et. al.  
Activators of peroxisome proliferator-activated receptor alpha partially inhibit 
mouse skin tumor promotion.  (2000) Mol Carcinog 29(3):134-142. 
 
Tibiletti MG, Sessa F, Bernasconi B, Cerutti R, Broggi, et. al.  A large 6q deletion 
is a common cytogenetic alteration in fibroadenomas, pre-malignant lesions, and 
carcinomas of the breast.  (2000) Clin Cancer Res 6(4):1422-1431. 
 
Tibiletti MG, Bernasconi B, Furlan D, Bressan P, Cerutti R, et. al.  Chromosome 
6 abnormalities in ovarian surface epithelial tumors of borderline malignancy 
suggest a genetic continuum in the progression model of ovarian neoplasms.  
(2001) Clin Cancer Res 7(11):3404-3409. 
 
Tontonoz P, Hu E, Graves RA, Budavari A, and Spiegelman BM.  mPPARγ2: 
tissue-specific regulator of an adipocyte enhancer.  (1994) Genes & Dev 8:1224-
1234. 
 
Tontonoz P, Hu E, Devine J, Beale EG, and Spiegelman BM.  PPAR gamma2 
regulates adipose expression of the phosphoenolpyruvate carboxykinase gene.  
(1995) 15:351-357. 
 
Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, et. al.  Terminal 
differentiation of human liposarcoma cells induced by ligands for peroxisome 
proliferator-activated receptor- gamma and the retinoid X receptor.  (1997) Proc 
Natl Acad Sci USA 94:1989-1984. 
 
Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, and Evans RM.  PPARγ 
promotes monocyte/macrophage differentiation and uptake of oxidized LDL.  
(1998) Cell 93:241-252. 
 
Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, et. al.  The 
mouse peroxisome proliferator-activated receptor recognizes a response element 
in the 5’ flanking sequence of the rat acylCoA oxidase gene.  (1992) EMBO J 
11:433-439. 
 
Urso C.  Are growth phases exclusive to melanoma?  (2004) J Clin Pathol. 
57(5):560. 
 
 - 31 - 
Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, et. al.  The peroxisome 
proliferator-activated receptor δ promotes lipid accumulation in human 
macrophages.  (2001) J Biol Chem 276:44258-44265. 
 
Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, et. al.  
Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung 
carcinomas.  (2001) J Natl Cancer Inst 92:1303-1307.   
 
Vladislava OM and Bar-Eli M.  Transcriptional control of the melanoma 
malignant phenotype.  (2008) Cancer Biology and Therapy 7(7):997-1003. 
 
www.cancer.org 
 
Wagner JW and Fisher DE.  Melanocyte signaling pathways and the etiology of 
melanoma.  (2005) Drug Discovery Today: Disease Mechanisms 2(2):179-183. 
 
Wahli W.  Peroxisome proliferator-activated receptors (PPARs): from metabolic 
control to epidermal wound healing.  (2002) Swill Med Wkly 132:83-91. 
 
Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, et. al.  
Modulation of keratinocyte gene expression and differentiation by PPAR-
selective ligands and tetradecylthioacetic acid.  (2001) J Invest Dermatol 116:702-
712. 
 
Wood WR, Seftor EA, Lotan D, Nakajima M, Misiorowski RL. et. al. Retinoic 
acid inhibits human melanoma tumor cell invasion.  (1990) Anticancer Research 
10:423-432. 
 
Xia W, Unger P, Miller L, Nelson J, and Gelman IH.  The Src-Suppressed C 
Kinase Substrate, SSeCKS, Is a potential metastasis inhibitor in prostate cancer.  
(2001) Cancer Res 61:5644-5651. 
 
Xia W and Gelman IH.  Mitogen-induced, FAK-dependent tyrosine 
phosphorylation of the SSeCKS scaffolding protein.  (2002) Exp Cell Res 
277:139-151. 
 
Xu XC.  Tumor-suppressive activity of retinoic acid receptor-beta in cancer.  
(2007) Cancer Lett 253:14-24. 
 
 
 
 
 
 
 
 
 - 32 - 
Rationale for Thesis Projects___________________ 
 
 
     Melanocytes play a very important role in the normal physiology of the skin.  
These cells produce the pigment melanin, which not only affects the visible color 
of our skin, but also functions as a photoprotective substance that is able to 
dissipate more than 99.9% of absorbed UV radiation as heat.  UV radiation is a 
potent DNA damaging agent and is a causation of skin carcinogenesis.  UV-
induced DNA damage in primary cultures of melanocytes showed an increased 
frequency of pyrimidine dimers, which are signatures of UV mutation (Mouret, et. 
al., 2012).  The genes that are principal targets of mutations in melanoma are 
commonly oncogenes and tumor suppressor genes.  The most frequent mutations 
include genes that cause constitutive activation of RAS and RAF proteins, 
p16INK4a gene deletions, mutations in the melanocortin 1 receptor (MC1R), PTEN, 
and PI3K genes.  Mutations in these genes can change the expression and/or 
activity of transcription factors.  The transcription factor AP-1, as well as the 
ligand activated nuclear receptors RARs, RXRs and PPARs have exhibited 
altered expression and activity in melanoma cells. 
     The purpose of my thesis research was to study specific genes and proteins that 
changed during melanoma progression.  Specifically, I was interested in 
determining whether these altered pathways could be ameliorated by the dietary 
component Vitamin A resulting in cancer cell differentiation and loss of 
malignancy.  I focused initially on a family of ligand activated nuclear receptors, 
the PPARs, due to their interaction with RXRs.  Subsequently, I studied the gene 
AKAP12, which was identified through microarray analysis as exhibiting the 
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highest degree of stimulation in atRA-treated melanoma cells.  The following 
chapters explain the results from these two studies. 
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Chapter 2:  PPARα/γ Expression and Activity in 
Mouse Melanocytes and Melanoma Cells_________ 
 
     The information presented in this chapter is the author’s contribution to the 
following manuscript “PPARα/γ Expression and Activity in Mouse and Human 
Melanocytes and Melanoma Cells.”  This manuscript was accepted for 
publication in Pharmaceutical Research (2008) 25:1326-1333.  Reprinting for 
dissertation is part of the author’s rights and permission is not required from 
Springer Science Business Media, LLC. 
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Abstract 
     The purpose of this research was to examine the expression of PPARs and the 
effects of PPARα and PPARγ agonists on the growth of mouse melanocytes and 
melanoma cells.  Expression of PPARα, β, and γ mRNA levels in melan-a mouse 
melanocytes and B16 mouse melanoma cells was assayed quantitatively by RT-
PCR, while quantitative PPARα mRNA levels were measured by QuantiGene 
assay.  The effects of natural (PGJ2, leukotriene B4) and synthetic (ciglitazone, 
troglitazone, WY14643) PPAR ligands on cell growth were also examined, while 
PPAR transcriptional activity was determined by a PPRE-reporter gene assay.  
B16 melanoma cells produced more PPARα and PPARγ protein than melan-a 
melanocytes.  However, B16 PPARα mRNA levels were similar to those of 
melan-a melanocytes.  The PPARγ-selective agonists were able to significantly 
inhibit the cell growth of both melan-a melanocytes and B16 mouse melanoma 
cells, while PPARα-selective agonists had limited effects on melanoma growth.  
The increased expression of PPARα and γ protein in B16 cells compared to 
melan-a melanocytes may be a common occurrence in melanoma, however, its 
biological significance remains to be determined.  Selective PPARγ agonists may 
prove useful to arrest the growth of some melanomas.   
 
Introduction 
     PPARs are members of the nuclear receptor superfamily of ligand-activated 
transcription factors.  There are three subtypes-PPARα, PPARβ/δ, and PPARγ.  
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Endogenous fatty acids and synthetic agonists activate these receptors.  Upon 
activation, PPARs regulate genes involved in lipid and glucose homeostasis 
(Green, 1995; Eschler and Wahli, 2000; Berger and Moller, 2002).  These 
receptors also regulate normal and disease related processes, including embryo 
implantation, inflammation, cell cycle progression, differentiation and 
tumorigenesis (Berger and Moller, 2002).  
     Activation of PPARs decreases cell growth and induces differentiation in 
many cancer cell lines (Mueller, et. al., 1998; Kawa, et. al., 2002; He, et. al., 
2005).  However, there is little information on the PPAR subtypes and relative 
levels of PPAR expressed in melanocytes and melanoma cells (Kang, et. al., 
2004).  We therefore characterized the types of PPARs, level of PPARα and 
PPARγ mRNA and protein, and the ability of PPAR-selective agonists to inhibit 
proliferation in mouse melanocytes and melanoma cells. 
 
Materials and Methods 
PPAR Agonists 
     Leukotriene B4 was obtained from Sigma Chemical Co. (St. Louis MO).  
Ciglitazone, 15-Deoxy-∆12,14-prostaglandin J2 (PGJ2), and WY14643 were 
obtained from Biomol Research Laboratories, Inc. (Plymouth Meeting, PA).  
Troglitazone was obtained from Axxora, LLC (San Diego, CA).  A stock solution 
of LTB4 was made using 102 µg/ml in 100% ethanol and diluted to 0.01, 0.05 and 
0.1 µM concentrations in DMEM complete media.  For ciglitazone, troglitazone, 
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and WY14643, 10-2M stock solutions were made using DMSO and diluted to 1, 5, 
and 10 µM concentrations in DMEM complete media. 
 
Cell Culture 
     B16 mouse melanoma cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM; GIBCO/Invitrogen, Carlsbad, CA), as described previously 
(Boskovic, 2004).  Melan-a cells (Dr. D. Bennett, Department of Anatomy and 
Developmental Biology, St. George’s Hospital Medical School, London, 
England) were grown in RPMI 1640 medium as previously described (Boskovic, 
2004).  Cells were maintained in a 10% CO2/90% air humidified atmosphere.  
Both the B16 (ATCC, Manassas, VA) and melan-a cell lines were derived from 
the C57/BL6 mouse.          
 
Western Blots and Antibodies 
     Equal amounts of protein (50µg) were separated using 7.5% SDS-PAGE gels 
and transferred to blotting membranes.  The blots were blocked with 5% non-fat 
dry milk overnight at 4°C and probed with the following antibodies:  monoclonal 
mouse PPARα for mouse melanocytes and melanoma 1:250 (Affinity 
Bioreagents, Golden CO); and polyclonal PPARγ2 1:500 (Cell Signaling 
Technology, Beverly, MA).  Secondary antibodies were polyclonal HRP-linked 
anti-rabbit IgG (Cell Signaling Technology, Beverly, MA) and monoclonal anti-
mouse IgG (Amersham, Chicago, IL) used at 1:3000.  Blots were developed with 
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ECL reagents (Amersham, Chicago, IL), and the chemiluminescent signal 
quantified with a Chemi-doc Imager (Bio-Rad). 
 
Reverse Transcriptase Polymerase Chain Reaction 
     Total RNA was extracted using Tri-Reagent (Sigma Chemical Co.) and 
reverse transcribed using the RT for PCR kit (Clontech, Palo Alto, CA).  PCR 
was performed using the following primers: mouse; PPARα forward 5’-
AGCTGGTGTAGCAAGTGT-3’, reverse 5’-TCTGCTTTCAGTTTTGCTTT-3’ 
product 163 bp; PPARβ/δ forward 5’-CCCGGGAAGAGGAGAAAGAG-3’, 
reverse 5’-AAAGCGGATAGCGTTGTGC-3’ product 402 bp; and PPARγ2 
forward 5’-CCAGTGTGAATTACAGAAATCTCTGTTTTATGCTG-3’, reverse 
5’-AGAACGTGATTTCTCAGCC-3’ product 120 bp.  The PCR was performed 
with the AccuPrime Taq DNA Polymerase System (Invitrogen) with the 
following conditions: PPARα and PPARγ, 40 cycles of 94° C, 30 s; 65° C, 30 s; 
68° C, 1minute; PPARβ/δ, 40 cycles of 94° C, 30 s; 65° C, 30 s; 68° C, 1 minute.  
PCR products were electrophoresed through 1% agarose gels and visualized with 
ethidium bromide. 
 
QuantiGene Assay 
     RNA from cells was extracted with Tri-Reagent.  QuantiGene assays 
(Panomics, Inc., Freemont, CA) were performed according to the manufacturer’s 
protocol.  Briefly, 2 µg of RNA in 10 µl was loaded into each well of a 96 well 
plate and incubated with PPARα, β-actin target probes, in conjunction with 
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dendrimer DNA amplifier and labeled probes at 56° C overnight.  Following 
several washes with QuantiGene buffer, chemiluminescent substrate was added to 
the wells and incubated at 56° C for 30 minutes.  The reaction signals (relative 
light units – RLU) were measured using a Centro LB 960 luminometric plate 
reader (W. Nuhsbaum Inc., McHenry, IL). 
 
 
Reporter Gene Assays 
     B16 cells were seeded at a density of 3x105 per 60 mm tissue culture dish.  
Each assay was performed in triplicate.  The mouse melanoma cells were 
transfected with β-galactosidase (β-galactosidase Enzyme Assay System, 
Promega Corp., Madison, WI); pGL-2x-PPRE-Luciferase reporter plasmid (Dr. 
John Capone, Department of Biochemistry, McMaster University, Hamilton, ON, 
Canada); pSV sport PPARα or pSV sport-PPARγ expression vectors (Dr. Bruce 
Spiegelman, Dana-Farber Cancer Institute, Boston, MA).  The plasmid DNA ratio 
was 1:10:10 respectively.  Lipofectamine plus reagent kit was used to transfect 
the cells (Invitrogen).  After transfection, media, serum and appropriate agonists 
were added to the cells.  Cells were harvested after 48h, and assayed for β-
galactosidase and luciferase activity using kits from Promega Corp.  
Chemiluminescence was determined using a Lumat LB 9501 Luminometer.  
Transfection efficiency was corrected by measuring the amount of β-
galactosidase activity. 
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Statistics 
     Samples for each experiment were performed in triplicate (n=3).  Biological 
repeats for each experiment were performed at least three times, or more if 
necessary.  Statistical significance determined using the SigmaStat analysis 
program.  Sample comparisons were made using One Way ANOVA (analysis of 
variance).  Probability of significance was determined using the Student-
Knewman Keuls t-test.  Standard error bars are shown.      
 
 
 
Results 
Expression of PPAR subtypes 
     The expression of PPAR subtypes in mouse melan-a melanocytes and B16 
mouse melanoma cancer cells was examined using RT-PCR.  Figure 2.1 shows 
that mouse melanocytes and melanoma cells express mRNA for PPARα, 
PPARβ/δ, and PPARγ2. 
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Figure 2.1.  Expression of PPAR subtype mRNA in mouse melanocytes and 
melanoma cells.  RNA was isolated, purified and reverse transcribed using the 
Advantage RT-for PCR kit (Clontech, Palo Alto, CA).  PCR analysis was 
performed using the specific primers for each subtype listed in the “Materials and 
Methods”. 
 
     Because RT-PCR provides only qualitative results, we also measured the 
relative amount of PPARα and PPARγ protein and PPARα mRNA in these cells 
using Western blotting and QuantiGene assays respectively.  Unfortunately, we 
could not Quantitate PPARγ mRNA levels because there are no capture probes for 
this RNA species.  Results show that B16 melanoma cells expressed higher levels 
of PPARα (52 kD) and PPARγ (56 kD) protein compared to non-malignant 
melan-a cells (Figure 2.2).  Quantitation of the immunoblots revealed that B16 
mouse melanoma cells have threefold more PPARα and 40% more PPARγ 
protein than melan-a mouse melanocytes (Figure 2.2A and B). 
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Figure 2.2.  Expression of PPAR subtype protein in mouse melanocytes and 
melanoma cells.  Proteins were separated and PPARs detected by selected 
antibodies as outlined in “Materials and Methods”.  Relative amounts of PPARα 
and PPARγ were determined by densitometry (bar diagram) and corrected for the 
amount of actin in each sample.  A and B represent PPARα and PPARγ protein 
expression respectively in mouse melan-a melanocytes and B16 melanoma cells.  
A representative analysis is shown.  The experiments were repeated three 
additional times with the same qualitative results. 
     QuantiGene assays (Panomics) revealed that mouse B16 melanoma cells had 
60% less PPARα mRNA compared to the melan-a melanocytes (Figure 2.3).  
This is in stark contrast to the level of PPARα protein, which is threefold higher 
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in B16 relative to melan-a cells.  While there is not a strong correlation between 
mRNA and protein levels for this receptor in the mouse melanoma cells, it does 
suggest that the expression of PPARα it regulated at the translational level.   
 
 
Figure 2.3.  Quantitation of PPARα mRNA levels in mouse melan-a melanocytes 
and B16 melanoma cells.  The QuantiGene assay system was used to determine 
relative amounts of PPARα mRNA.  Cell lysates were loaded into wells of a 
QuantiGene capture plate and hybridized to probes specific for mouse PPARα 
mRNA.  A representative experiment representing the ratio of PPARα expression, 
corrected for β-actin is shown.  This experiment was repeated twice with similar 
results. 
 
 
40% ↓ 
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Effect of PPARα and PPARγ Agonists on Cell Proliferation 
     We measured the effect of PPAR-selective agonists on melanocyte and 
melanoma cell proliferation.  Agonist concentrations were chosen that would 
maximize receptor subtype specificity.  The natural PPARγ agonist, PGJ2, 
inhibited the growth of both melan-a melanocytes and B16 melanoma cells (27% 
and 33% respectively) (Figure 2.4A).  The synthetic PPARγ agonist ciglitazone 
also inhibited the growth of melan-a and B16 cells (33% and 22% respectively) 
(Figure 2.4B), while troglitazone, a synthetic and highly selective PPARγ agonist, 
was only able to inhibit the growth of B16 melanoma cells (36%) (Figure 2.4C).   
     The synthetic PPARα agonist, WY14643, had no significant effect on 
proliferation of melan-a and B16 cells (Figure 2.4D), while the natural PPARα 
agonist LTB4, inhibited the growth of the melan-a cells but not B16 cells (Figure 
2.4E). 
Figure 2.4A. 
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Figure 2.4B. 
Melan-a and B16 Cells Treated with Ciglitazone
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Figure 2.4C. 
Melan-a and B16 cells Treated with Troglitazone
0
20
40
60
80
100
120
Control 1uM 5uM 10uM
Concentration
%
 C
on
tro
l o
f M
el
an
-a
 a
nd
 B
16
 
Ce
ll 
Nu
m
be
r
Melan-a
B16
 
 
22%↓ 
∗ 
33%↓ 
+ 
+ 
∗ ∗ 
+ 
36%↓ 
 - 46 - 
Figure 2.4D. 
Melan-a and B16 Cells Treated with WY14643
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Figure 2.4E. 
Melan-a and B16 Cells Treated with LTB4
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Figure 2.4.  Effect of PPAR agonists on mouse melan-a melanocytes and B16 
melanoma cell proliferation. (A, PGJ2; B, ciglitazone; C, troglitazone; D, 
WY14643; and E, LTB4)  Triplicate dishes of cells were treated with the indicated 
concentration of agonist for 48h (previously determined to be the most effective 
treatment time), then harvested and cell number determined by cell counts with a 
hemocytometer.  Data are presented as cell number after 48h treatment with 
appropriate agonist.  The error bars represent the SEM of triplicate dishes at each 
concentration of agonist tested.  All experiments were repeated a minimum of 
three times with similar results.  (∗ = Melan-a; + = B16; significantly different 
relative to control cells p<0.05) 
 
PPAR Trans-Activation 
     PPAR agonists have non-receptor-mediated effects.  For example, PGJ2 alters 
NF-κB activity (Okano, et. al., 2003). Therefore, we compared the concentration-
dependent ability of the three PPARγ agonists PGJ2, Ciglitazone, and 
Troglitazone, as well as the PPARα agonist WY14643, to stimulate PPRE 
reporter gene activity in B16 mouse melanoma cells and correlated this activity 
with their ability to inhibit the growth of the same cell line.  B16 cells were co-
transfected with either the PPARγ or PPARα expression plasmid since 
endogenous PPRE reporter gene activity was too low to be accurately detected.  
The PPARγ agonists, PGJ2 and ciglitazone stimulated PPRE reporter gene 
activity in a dose dependent manner (Figure 2.5A and B).  There was also 
significant reporter gene activity when B16 cells were treated with troglitazone or 
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WY14643 (Figure 2.5C and D).  The ability of these agonists to stimulate the 
reporter gene correlated with their ability to inhibit B16 cell proliferation (Figure 
2.4).  However, the amount of growth activity was small (22-36%), relative to the 
increase in reporter gene activity, which ranged from 2-fold (WY), to 5-fold 
(Cig).   
 
Figure 2.5.  Ability of PPAR agonists to increase PPRE reporter gene expression.  
A β-galactosidase expression plasmid and a 2x PPRE pSG5-luciferase plasmid 
were transiently co-transfected into B16 cells.  The transfection mixture also 
A.
 
B. 
C. D. 
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contained either pSV-PPARγ (A, B, and C) or pSV-PPARα (D), with a plasmid 
DNA ratio of 1:10:10 respectively.  Cells were harvested and assayed for β-
galactosidase and luciferase activity 48h after agonist addition.  The error bars 
represent the SEM of triplicate dishes of transfected cells.  The experiment was 
repeated three times with similar results.  (∗p<0.001) Significantly different 
relative to transfected cells without agonist.  (A PGJ2; B Ciglitazone; C 
Troglitazone; D WY14643).   
 
Discussion 
     Aberrant expression of PPARs has been found in several types of cancers such 
as colon, prostate, lung, skin, breast, and liposarcomas (Tontonoz, et. al., 1997; 
Inoue, et. al., 2001; Suchanek, et. al., 2002; Segawa, et. al., 2003; Aung, et. al., 
2005; Nijsten, et. al., 2005).  Overexpression of PPARα might contribute to 
tumorigenesis through its ability to stimulate proliferation by enhancing 
expression of genes encoding CDK-1 and CDK-4 and c-myc (Miller, et. al., 1996; 
Zang, et. al., 2006).  In contrast, expression and activation of PPARγ is reported 
to stimulate differentiation and inhibit cell proliferation of several carcinoma-
derived cell lines (Mueller, et. al., 1998; Kawa, et. al., 2002; Park, et. al., 2005).  
In the skin, PPARα is involved in maintaining epidermal barrier function as well 
as differentiation and wound healing (Di-Poi, et. al., 2004; Michalik, et. al., 
2005).  The types of PPAR expressed in normal melanocytes and whether their 
expression is altered in melanoma cells has not been well studied.  We found that 
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all of the PPAR subtypes, including PPARβ/δ are expressed at the mRNA level 
by mouse melanocytes and melanoma cells.  Quantitative assay of mRNA levels 
revealed that melan-a melanocytes had more PPARα mRNA than B16 melanoma 
cells.  In contrast, B16 cells had much higher amounts of PPARα protein relative 
to melan-a melanocytes.  These findings suggest there is significant regulation of 
PPARα at the protein level, possibly through efficiency of translation.  The 
amount of PPARγ was also higher in B16 melanoma cells.  Unfortunately, due to 
a lack of a PPARγ capture probe for the QuantiGene assay, we could not 
quantitatively compare the mRNA and protein levels for this PPAR subtype to see 
whether it also might be subjected to regulation at the protein level. 
     Several groups have reported that PPARγ-selective ligands can inhibit the 
growth of human melanoma cells (Plachaa, et. al., 2003; Freudlsperger, et. al., 
2006; Lee, et. al., 2007).  However, in several of these reports, significant 
inhibition of proliferation did not occur until 20 µM or higher concentrations of 
ligand.  Many natural and synthetic PPAR ligands lose their selectivity at these 
concentrations (Selmandi, et. al., 2005).  We therefore limited our ligand 
concentrations to a maximum of 10 µM.  While the effects on cell growth were 
significant, the compounds were only moderately effective at inhibiting 
proliferation using this concentration.    
     It is curious that B16 mouse melanoma cells express high levels of both 
PPARα and γ relative to their non-transformed counterpart, melan-a melanocytes, 
yet are either not growth inhibited by receptor-selective ligands or their inhibition 
is similar to normal melanocytes.  One possible reason for this may be due to 
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changes in expression or activity of PGC-1α (PPARγ Co-activator 1α). This 
cofactor is involved in regulating the activity and binding specificity of PPAR 
receptors to their response elements.  This process is important for activation of 
specific target genes.  The reduction of PGC-1α expression has been implicated in 
type II diabetes; however, I found very little information on PGC-1α expression 
and activity in melanoma.    
     Because it has been reported that PPAR ligands can have receptor-independent 
effects (Okano, et. al., 2003; Chaffer, et. al., 2006), we compared their 
concentration-dependent ability to activate PPRE reporter gene activity with their 
concentration-dependent ability to inhibit the growth of B16 mouse melanoma 
cells.  In general, we found a good correlation between these two activities in B16 
cells.  However, the degree of growth inhibition did not correlate as well with the 
level of gene activity.  For the reporter gene assays, we co-transfected plasmids 
encoding the PPARγ and PPARα proteins into the B16 cells, since it was difficult 
to detect endogenous ligand-activated reporter gene activity.  Therefore, it is 
possible that the endogenous PPARα and γ receptors in the B16 melanoma cells 
are defect in transcriptional activation despite being over-expressed relative to 
normal melan-a melanocytes.  One reason for this may be due to the constitutive 
activation of the MAPK pathway.  The B16 cells contain an NRAS mutation that 
drives the activation of ERK1/2.  The phosphorylation of specific serines in the 
N-terminal region, regulate the activity of the receptors in a ligand-independent 
manner.  This leads to a change in its conformation and a decrease in its 
transcriptional activity.     
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Conclusion 
     In summary, we have found that mouse melan-a melanocytes and B16 
melanoma cells express PPARα, PPARβ/δ, and PPARγ2 receptors.  The 
melanoma cells overexpress PPARα and PPARγ protein relative to melanocytes, 
however, there is a discordance between RNA and protein levels for these 
receptors.  The ability of PPAR ligands, at concentrations where selectivity was 
maintained, to inhibit replication of these cells was variable and did not correlate 
as well with the expression level of the relevant PPAR.  We did not find 
convincing evidence that PPARs are involved in development or maintenance of 
the melanoma phenotype as there was no observable change in their physical 
characteristics.  However, PPARγ ligands at pharmacological concentrations 
might be useful in the treatment of certain melanoma lesions (Liu, et. al., 2006). 
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Rationale for Discontinuing PPAR Project and 
Initiating a New Project Involving Retinoic Acid 
and AKAP12________________________________  
 
     Data I acquired in the PPAR part of my thesis work were published together 
with data obtained by co-author Dr. Caroline Mills and her work with PPARs in 
human melanoma cells.   
     To ascertain the effect of PPARα down-regulation on melanoma cell biology, 
Dr. Mills transfected SK-mel28 human melanoma cells with siRNA to PPARα in 
order to down-regulate the expression of this gene.  Even though QuantiGene 
assays determined that there was >80% knockdown of PPARα after 96 hours 
after transfection, there was no change in any biological parameter that was 
measured.  Cell growth, morphology and viability of SK-mel28 melanoma cells 
were examined in these cells and no changes in the cell phenotype were observed.  
In addition, a known transcriptional target of PPARα, medium chain acyl CoA 
dehydrogenase (MCAD) protein was measured by Western blotting to determine 
whether PPARα knockdown decreased the amount of this protein.  There was no 
change in MCAD protein levels between SK-mel28 cells transfected with PPARα 
siRNA or control siRNA, which could be because there was not a complete 
knockdown of protein expression.  The amount of remaining protein would still 
be able to activate gene transcription.  Also, these receptors have redundant 
functions; therefore, the PPARβ/δ or γ proteins may act as a substitute for 
PPARα.  Due to the inability of PPARα downregulation to induce changes in the 
melanoma phenotype, we decided to end this project and search for another 
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avenue of research that might lead to an understanding of how retinoids can cause 
growth arrest and differentiation in responsive melanoma cells. 
     During this same time frame, our laboratory was using microarrays for gene 
expression profiling to determine the effect of atRA treatment on B16 melanoma 
gene expression.  The results of the microarray analysis showed that after 48 
hours of atRA treatment, there was one gene, AKAP12 whose expression was 
increased 28 fold relative to control cells.  A thorough literature search did not 
yield any publications describing this gene or its regulation in melanocytes or 
melanoma cells.  Therefore, with the permission and encouragement of my thesis 
advisor, Dr. Richard Niles, I initiated a study of the expression, atRA regulation 
and possible role of AKAP12 in melanoma.  
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Chapter 3: Retinoic Acid Regulated AKAP12 
Expression in Mouse and Human Melanocytes and 
Melanoma Cells______________________________ 
 
Abstract 
 
     Retinoic Acid (atRA) is the most biologically active form of Vitamin A and 
inhibits the growth of mouse and human melanoma cells.  Profiling of atRA 
regulated genes in B16 melanoma identified AKAP12, a scaffolding protein 
involved in assembling multi-protein signaling complexes, as the most highly 
induced gene at 48 h of atRA treatment.  In this chapter I report that atRA also 
regulates AKAP12 expression in human melanocytes and melanoma cells and 
provide evidence for the involvement of AP-1 in the regulation of AKAP12 gene 
expression.  Functional studies involving knockdown of AKAP12 expression 
using siRNA showed that AKAP12 was involved in the regulation of invasive and 
anchorage-independent growth properties.  The basal mRNA and protein levels of 
AKAP12 differed among human melanocytes and six human melanoma cell lines.  
Also, AKAP12 mRNA and protein was differentially induced by atRA in the 
different human melanoma cell lines.  There was a significant correlation between 
atRA induced increases in AKAP12 levels among the melanoma cell lines and the 
ability of atRA to inhibit proliferation.  In silico analysis of the AKAP12 
promoter region revealed 3 activator protein (AP-1) transcription factor binding 
sites.  Since atRA stimulates AP-1 activity in B16 melanoma cells (Desai and 
Niles, 1997; Huang, et. al., 2002), I examined whether AP-1 mediated the atRA 
induction of AKAP12.  Reporter gene assays showed that atRA treatment 
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increased AP-1 activity in WM3248 and WM239 human melanoma cells.  Co-
transfection of these melanoma cells with an AP-1 reporter plasmid and a 
dominant-negative c-fos (A-fos) resulted in inhibition of atRA induced AP-1 
activity.  Unexpectedly, transfection of the A-fos plasmid into human melanoma 
cells enhanced rather than inhibited atRA induced AKAP12 expression.  These 
data suggest that rather than mediating the stimulation of AKAP12 expression by 
atRA, AP-1 attenuates the induction of this gene.  
 
Introduction 
   The most aggressive form of skin cancer is cutaneous malignant melanoma 
(CMM).  Although it accounts for only 4% of all skin cancers, it is responsible for 
nearly 80% of the total number of skin cancer related deaths in the United States.  
The incidence of melanoma is steadily growing, becoming one of the fastest 
growing cancers worldwide (Boyle, 2011; www.cancer.org).  Melanoma 
progression undergoes distinct phases (Urso, 2004; Melinkova and Bar-Eli, 2008).  
In the radial growth phase (RGP), the cancer cells spread horizontally and are 
confined to the epidermis.  If detected during this phase of development surgical 
excision leads to a very high cure rate.  In the vertical growth phase (VGP), the 
melanoma cells penetrate vertically through the basement membrane and invade 
the dermis and underlying tissues.  The metastatic phase (Met) is characterized by 
the ability of melanoma cells to spread to distant organs and at this stage the 
disease is usually incurable.  Melanoma is among the most aggressive tumor types 
because of its high capacity to metastasize and its resistance to treatment.  
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Currently, there are few effective therapies available for the treatment of 
metastatic melanoma (Lens, 2008; Boyle, 2011).    
     Retinoids are natural or synthetic derivatives of Vitamin A.  All-trans retinoic 
acid (atRA) is the active metabolite of Vitamin A and inhibits growth and/or 
induces differentiation in a variety of tumors (Nettesheim, 1980; Garattini, et. al., 
2008), including mouse and human melanoma (Fliegel, et. al., 1992; Desai, et. al., 
2000; Niles, 2003).  Our laboratory studies the mechanism by which atRA exerts 
its biological effects in melanoma cells.  Gene expression profiling during a 4-48 
hour treatment of B16 mouse melanoma cells with atRA identified the gene 
coding for A-Kinase Anchoring Protein 12 (AKAP12) as the highest induced 
gene at the 48 hour time point. 
          AKAP12, also known as AKAP250 or Gravin, is a member of a family of 
structurally diverse but functionally similar scaffolding proteins.  These proteins 
are involved in assembling multi-protein signaling complexes that function to 
promote efficient and specific enzyme/substrate reactions in a spatial and 
temporal manner (Gelman, 2002).  The hAKAP12 gene is located on 
chromosome 6q24-25.2, which has been found to be a deletion hotspot in 
advanced prostate, breast and ovarian cancer, and may encode one or more tumor 
suppressor genes (Cooney, et. al., 1996; Noviello, et. al., 1996; Tibiletti, et. al., 
2000; Tibiletti, et. al., 2001; Gelman, 2002; Abdollahi, et. al., 2003; Gorringe, et. 
al., 2009).   
     The objective for this study was to determine whether atRA also stimulated 
AKAP12 protein and RNA expression in human melanocytes and a series of 
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human melanoma cell lines established from different stages of malignant 
progression.  I also examined the possible intermediary role of RA-induced AP-1 
activity on AKAP12 gene regulation.  AKAP12 was differentially expressed and 
induced by atRA in melanocytes and in six different melanoma cell lines.  There 
was a significant correlation between atRA’s ability to induce AKAP12 
expression and its ability to inhibit growth.  Unexpectedly, AP-1 was 
demonstrated to be a negative regulator of AKAP12 mRNA expression.  Down-
regulation of AKAP12 expression in mouse and human melanoma cells led to an 
increase in invasiveness and an increased ability to grow in an anchorage-
independent manner.  
 
Materials and Methods 
Cell Culture 
Samples of human epidermal neonatal lightly pigmented melanocytes (HEMn-
LP) were obtained from Cascade Biologics, Portland, OR, and maintained in 
Medium 254 supplemented with 5 ml human melanocyte growth serum (HMGS) 
and 1 ml penicillin, streptomycin and amphotericin B (PSA) solution per 500 ml 
bottle.  SbCl2 and WM3211 cells were isolated from radial growth phase 
melanomas, WM1366 and WM3248 were isolated from vertical growth phase 
melanomas, and WM9 and WM239 cells were isolated from metastatic 
melanomas.  These cell lines were obtained from Meenhard Herlyn, D.V.M., 
D.Sc., Professor and Director of the Molecular and Cellular Oncogenesis Program 
at The Wistar Institute, Philadelphia, PA.  Cells were grown as described (Mills, 
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et. al., 2009).  The B16 mouse melanoma cells (ATCC, Manassas, VA) were 
grown in RPMI 1640 media (Gibco/Invitrogen, Carlsbad, CA) with 10% FBS and 
1% pen/strep.  All cells were maintained at 37º in cell culture incubators with a 
5% CO2/95% air humidified atmosphere. 
 
Retinoic Acid 
All-trans retinoic acid was purchased from Sigma Chemical Co. (St. Louis, MO).  
All experiments involving the use of RA were conducted under yellow light to 
prevent photo-oxidation of this retinoid.  A 10 mM stock solution was prepared in 
DMSO.  Control cells received the same volume of vehicle.  Stock solution was 
diluted to the desired final concentration in tissue culture medium.   
 
 RNA Extraction and DNA Microarray Analysis 
Control and 10 µM atRA treated B16 cells were harvested at 4, 10, 24, and 48 
hours after treatment.  RNA was extracted using TRI Reagent (Sigma Chemical 
Co., St. Louis, MO) according to the manufacturer’s suggested protocol.  
Microarray gene profiling was performed as previously described (Estler, et. al., 
2008).  The calculated log ratios were compared for significant deviation from 
zero using one-class Significance Analysis of Microarrays (SAM) (Tusher, et. al., 
2001).  SAM was performed with the maximum number of unique permutations 
available.  Delta values were chosen to give a median False Discovery Rate of 
10%.  This setting allowed for the detection of RARβ expression, which is used as 
a control and is a direct target gene of RA.  
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QuantiGene Analysis 
RNA from control and 10 µM atRA stimulated B16 cells was extracted using TRI 
Reagent (Sigma Chemical Co., St. Louis, MO).  QuantiGene assays were 
performed according to the manufacturer’s protocol.  Briefly, 2 µg/10 µl RNA 
was loaded into each well of the 96 well plate and incubated overnight at 56° C 
with AKAP12 and β-actin target probes, in conjunction with dendrimer DNA 
amplifier.  Following several washes with supplied buffer, chemiluminescent 
substrate was added to the wells and the plates incubated at 56° C for 30 minutes, 
and luminescence measured on a Centro LB 960 luminometric plate reader (W. 
Nuhsbaum Inc., McHenry, IL). 
 
Western Blot Analysis 
HEMn-LP, SbCl2, WM3211, WM3248, WM1366, WM239, and WM9 cells were 
treated +/- 10 µM atRA for 48 hours and harvested in lysis buffer containing 
Complete Mini Protease Inhibitor (Roche Diagnostics, Mannheim, Germany).  
Protein concentration was measured with a Nanodrop spectrophotometer 
(Nanodrop Technologies, Wilmington, DE) and 30 µg of total cellular protein 
from control and treated cells was separated on 5% gels and transferred to 
nitrocellulose membranes.  Membranes were blocked with 5% BSA at 4° C 
overnight and then probed with the pAKAP12 antibody (1:500) (AbCam, 
Cambridge, MA) at 4° C overnight, followed by an incubation with HRP-linked 
anti-goat IgG (1:1000) (Vector Laboratories, Burlington, CA) for 1 hour at room 
temperature.  Since this antibody was discontinued, Western blot analysis of 
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protein levels after siRNA transfection used a new pAKAP12 antibody (1:1000) 
(Novus Biologicals), followed by an incubation with HRP-linked anti-rabbit IgG 
(1:1000) (Cell Signaling).  The membranes were stripped using Re-Blot Plus 
antibody stripping solution (Chemicon International, Temecula, CA).  Next, the 
membranes were incubated with polyclonal β-Catenin antibody (1:500) (Sigma 
Chemical Co., St. Louis, MO) at 4°C overnight, followed by an incubation with 
HRP-linked anti-rabbit IgG  (1:500) (Cell Signaling Technology, Beverly, MA).  
Blots were developed with ECL reagent (Amersham, Chicago, IL) and the 
chemiluminescent signal was quantified using a Chemi-Doc Imager (Bio-Rad).  
Protein loading was normalized using β-catenin expression.  The use of 5% gels 
only retains proteins that have a molecular weight of approximately 70kD or 
higher.  Most conventional proteins used to control for protein loading are lower 
than 70kD and therefore not appropriate for this type of gel.  Levels of β-catenin 
protein expression are similar in each of the cell lines used and determined to be a 
good housekeeping protein for these Western Blots.    
 
Quantitative RT-PCR 
HEMn-LP, SbCl2, WM3211, WM3248, WM1366, WM239, and WM9 cells were 
treated with +/- 10µM atRA for 48 hours.  RNA was extracted using the RNeasy 
Mini kit (#74104, Qiagen, Valencia, CA).  Purified RNA samples were dissolved 
in RNase–free water and quantified using a Nanodrop Spectrophotometer 
(Nanodrop Technology Inc., Wilmington, DE).  Each sample had a 260/280 ratio 
of greater than or equal to 1.8.  RNA quality was assessed by electrophoretic  
 - 65 - 
analysis on an Agilent Model 2100 Bioanalyzer (Santa Clara, CA).  All RNA 
samples used had RNA Integrity Numbers greater than 9. RNA was reverse 
transcribed to cDNA using an RT-for-PCR kit (Clontech, Palo Alto, CA) and 
random hexamer primers.  QPCR analysis was performed using ABI TaqMan 
probes for human or mouse isoforms of AKAP12 and an 18S probe was used as a 
control.  Assays were performed under conditions specified in the ABI TaqMan 
Gene Quantitation assay protocol.  For functional assays using siRNA, RNA was 
isolated 96 and 120 hours after transfection using the method stated above.  Data 
is expressed as ∆∆CT and normalized for 18S expression.  This method (∆∆CT) is 
used to measure relative changes in gene expression of a sample compared to that 
of a control.  Experiments were repeated a minimum of three times. 
 
Plasmid DNA Constructs 
The pGL2-4X-AP-1 –luciferase reporter plasmid was constructed as previously 
described (Desai and Niles, 1997).  The pCMV500 A-fos plasmid was kindly 
provided by Dr. Charles Vinson at the National Cancer Institute. 
 
Transient Transfections and Reporter Gene Assays 
B16 cells were seeded at a density of 1.5x105, while WM3248 and WM239 cells 
were seeded at a density of 3x105 in 60 mm tissue culture dishes.  Two groups of 
three plates each were co-transfected with the β-galactosidase (Promega Corp., 
Madison, WI) and the AP-1 luciferase reporter plasmids, while an additional two 
groups of three plates each were co-transfected with the β-galactosidase, AP-1 
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reporter and A-fos plasmids.  Fugene 6 Transfection Reagent (Roche Diagnostics, 
Indianapolis, IN) was used to transfect cells at a ratio of 1:3, Fugene 6 to µg of 
DNA.  After 5 hours of incubation with the transfection mixture, the media was 
changed to the regular growth media and the next morning 10 µM atRA was 
added to appropriate plates.  Cells were harvested after 48 hours of atRA 
treatment and β-galactosidase and luciferase activity assayed (Promega Corp., 
Madison, WI).  Chemiluminescence was measured using a Lumat LB 9501 
Luminometer and corrected for transfection efficiency as estimated by β-gal 
activity. 
 
siRNA Transfection 
AKAP12 expression was knocked down by treating cells with siRNA directed 
against AKAP12.  WM3248 and B16 cells were seeded at 3.5x105 and 1.5x105 
respectively into 60 mm tissue culture dishes.  After 24 hours, the medium was 
changed to 1.6 ml RPMI 1640 complete (seeding medium).  The transfection 
solution consisted of 800 µl ECR buffer with 50nM siGLO transfection indicator, 
and either 50nM control siRNA or 50 nM AKAP12 siRNA.  This mixture was 
incubated for 5 minutes at room temperature (RT).  Next, 30 µl of RNAifect 
reagent was added to the mixture and incubated for an additional 15 minutes at 
RT.  Lastly, 400 µl of the transfection mixture was added to each of the 
appropriate dishes and cells were incubated overnight.  The following morning 
the medium was changed to 4 ml RPMI 1640.  Control siRNA (siGenome Non-
targeting siRNA #1), mouse and human AKAP12 siRNA, and siGLO green 
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transfection reagents were purchased from Dharmacon/ThermoScientific, 
Lafayette, CO.  RNAifect reagents were purchased from Qiagen (Valencia, CA). 
 
Cell Invasion Assay 
Cytoselect 24-well Cell Invasion Assay kit was purchased from Cell Biolabs, 
Inc., San Diego, CA.  A suspension containing 5x105 cells/ml in serum-free RPMI 
1640 media was used for WM3248 (human) and B16 (mouse) melanoma cells.  
For B16 cells, the medium also contained 30 mg/ml serum albumin and, when 
appropriate, 1x10-7M atRA.  Inserts containing the dried basement membrane 
matrix were placed in appropriate wells of the plate and rehydrated with 300 µl of 
serum-free RPMI 1640 media for 1 hour at RT.  Next, the rehydration medium 
was removed and 500 µl of RPMI 1640 containing 10% FBS as a chemo-
attractant was added to the lower chamber and 300 µl (1.66x105) of cells were 
added to the upper chamber.  For B16 cells, control samples contained 30 mg/ml 
serum albumin, while test samples contained 30mg/ml albumin and 1x10-7M 
atRA.  Cells were incubated at 37° C for 48 hours.  To harvest invasive cells, non-
invasive cells were first removed from the top of the insert with a cotton swab.  
The inserts were then stained with cell stain dye solution for 10 minutes, washed, 
air dried and photographed (Olympus DP12 digital microscope camera system, 
Melville NY).  Next, the stained cells were solubilized with 200 µl extraction 
solution, and 100 µl from each sample transferred to a 96 well plate and OD 
measured at 560nM (Molecular Devices, Vmax kinetic microplate reader).  
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Anchorage-Independent Growth Assay 
CytoSelect 96-well Cell Transformation Assay (Soft Agar Colony Formation) 
kit was purchased from Cell Biolabs, Inc., San Diego, CA.  For the first layer of 
agar, a 1.2% agar solution was produced and solubilized using a microwave on 
high for 1 minute 15 seconds and allowed to cool in a 37° C water bath.  The, 
2xDMEM/20% FBS media was also warmed to 37° C in a water bath.  Equal 
volumes of these solutions were mixed (1:1) and 50µl of this mixture was added 
to each sample well of a sterile, 96-well, flat-bottomed, black microplate.  The 
plate was then transferred to 4°C for 30 minutes to allow the base layer to 
solidify.  For the second layer, cells were harvested and resuspended at 4x105 in 
RPMI 1640 media.  Control samples contained a similar volume of DMSO while 
test samples contained 3x10-7M atRA.  Cell suspensions were mixed 1:1:1 with 
1.2% agar and 2xDMEM/20% FBS media.  The final concentration of atRA was 
1x10-7M.  Control or atRA treated cells (10,000 cells/75 µl) were added to 
appropriate wells already containing the base agar layer.  The microwell plate was 
transferred to 4° C for 15 minutes to solidify the top agar layer.  Last, 100 ul of 
RPMI 1640 complete plus 10% FBS with either DMSO (Control) or 1x10-7M 
atRA was added to the appropriate wells.  The 96-well plate was incubated for 
either 48 or 72 hours at 37° C and 5% CO2.  Cells were examined and 
photographed under an Olympus DP12 digital microscope camera system.  The 
agar was solubilized and the cells lysed and combined to ensure a homogeneous 
mixture.  A 10 µl sample from each well was transferred to a black, 96 well plate 
for fluorescence measurement.  Just before use, the CyQuant working solution 
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was made by diluting CyQuant CR Dye 1:400 with 1X PBS.  A 90 µl aliquot of 
CyQuant working solution was added to each well.  The plates were immediately 
wrapped in foil and kept under low lighting conditions during a 10 minute 
incubation at room temperature.  Fluorescence was measured using a 
SpectraMAX GeminiEM fluorometer with a 485/538 nm filter set.  Fluorescence 
is proportional to the amount of DNA present in the cells. 
 
Statistics 
     Samples for each experiment were performed in triplicate (n=3).  Biological 
repeats for each experiment were performed at least three times, or more if 
necessary.  Statistical significance determined using the SigmaStat analysis 
program.  Sample comparisons were made using One Way ANOVA (analysis of 
variance).  Probability of significance was determined using the Student-
Knewman Keuls t-test.  Standard error bars are shown.  
 
Linear Regression Analysis  
     Linear regression analysis attempts to examine and model the relationship 
between two or more variables using a straight line.  A GraphPad Prism 5 
program was used to analyze data for this comparison.  The effect of atRA on 
AKAP12 mRNA expression (x) was compared to RA’s ability to inhibit growth 
(y) and analyzed for statistical significance. 
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Results 
 
Microarray analysis identifies AKAP12 as an atRA induced gene 
 
     In a previous study (Estler, et. al., 2008) we used gene expression profiling to 
identify genes in B16 melanoma cells whose expression is altered as a function of 
different times of atRA exposure.  The goal was to understand how a series of 
activated/repressed genes might contribute to the ability of atRA to inhibit 
proliferation and stimulate differentiation of this cell line.  This microarray 
analysis showed that AKAP12 expression is induced 25.6 fold (Table 3.1) in B16 
cells treated with atRA for 48 hours.  AKAP12’s degree of induction was the 
highest among the 717 genes whose expression was significantly increased by 
atRA at this time point.  To verify these microarray results, QuantaGene analysis 
was performed on RNA extracted from B16 melanoma cells treated for 24, 48 and 
72 hours with 10 µM atRA.  Retinoic acid induced a 6-fold and a 9-fold increase 
in AKAP12 mRNA at 48 and 72 hours respectively (Figure 3.2). 
Table 3.1.  Identification of AKAP12 as an atRA induced gene.   
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Table 3.1.  Gene expression profiling was performed on control and 10 µM atRA 
treated B16 mouse melanoma cells (Estler, et. al., 2008).  Microarray analysis 
identified AKAP12 as the highest induced gene at 48 hours of atRA treatment.  
The expression of AKAP12, as well as the control gene RARβ2, is shown after 4, 
10, 24, and 48 hours of RA treatment. 
 
Pathway analysis of microarray data 
     Data from the microarray were analyzed by the Pathway Studio v5.0 (Ariadne 
Genomics) program to identify and illustrate molecular connections between 
certain proteins encoded by the genes whose expression was significantly 
increased by atRA.  This program searches through the ResNet database for all 
known interactions between genes/proteins, which includes physical interactions, 
regulation of expression and protein modification, and expresses the result in 
graphical form (Figure 3.1).  Four major hubs for connectivity were identified.  
These were cell division cycle 2 protein (CDC2), checkpoint kinase 1 (CHEK1), 
CDC45 cell division cycle 45-like (CDC45L) and minichromosome maintenance 
deficient protein 6 (MCM6).  There were also three additional hubs that were 
identified which had relatively high numbers of interactions as well.  These were 
p53 protein (TP53), cyclin-dependent kinase inhibitor 1A protein 
(CDKN1A/p21/WAF1/CIP1) and cMYC (Estler, et. al., 2008). 
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Figure 3.1  Pathway Studio Analysis of Microarray Gene Set.  Protein hubs that 
have the most significant interactions (CDC2, CHEK1, CDC45L and MCM6) are 
marked with an asterisk (∗).  Although there are relatively large interactions 
stemming from TP53, p21 and cMYC, these proteins were not among the most 
statistically significant hubs.  Green color indicates a gene is upregulated whereas 
red color indicates that a gene is downregulated.  Color intensity reflects the 
expression ratio. 
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Figure 3.2.  Quantification of AKAP12 mRNA in B16 Mouse Melanoma Cells.  
Amount of AKAP12 mRNA expression in B16 cells treated +/- 10µM atRA.  The 
QuantaGene Assay system was used to determine relative amounts of AKAP12 
mRNA.  Cell lysates were loaded into 96 well capture plates and hybridized to a 
probe specific for mouse AKAP12 mRNA.  Relative light units were measured on 
a luminometer.  The amount of AKAP12 mRNA expression, corrected for β-
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actin, is shown.  {(AKAP12 untreated/β-actin)/(AKAP12 + RA/β-actin + RA)}.  
This experiment was repeated twice with similar results. 
 
AKAP12 Protein and mRNA Expression after atRA Stimulation   
     To establish if AKAP12 expression is also regulated by atRA in human 
melanocytes and melanoma cells, I examined the level of AKAP12 mRNA and 
protein from control and atRA treated normal human melanocytes (HEMn-LP), 
and the human melanoma cell lines SbCl2 & WM3211 (RGP); WM1366 & 
WM3248 (VGP); and WM239 & WM9 (Met).  These melanoma cell lines were 
chosen because they were established from tumors representing different stages of 
malignant progression.   
     All cell lines expressed AKAP12 protein and its expression was differentially 
induced after atRA treatment (Figure 3.3A).  The major isotype of AKAP12 in 
these cells is a 305/287kD doublet, with the top band designated as the α isoform 
and the lower band the β isoform (Gelman, 2002; Streb, et. al., 2004).  In 
untreated HEMn-LP, WM3211 and WM3248 cells, AKAP12α was the main 
isotype while untreated WM9 and WM1366 cells expressed equal amounts of the 
α and β isoforms.  Treatment of these cells with atRA for 48h induced expression 
of both isoforms, except in SbCl2 cells where the predominant isoform was 
AKAP12β.  Quantification of the protein expression revealed the following order 
of AKAP12 induction: SbCl2 (RGP) (3.54 fold), HEMn-LP human melanocytes 
(3.38 fold), WM3248 (VGP) (2.72 fold), WM239 (Met) (2.4 fold), WM3211 
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(RGP) (2.29 fold), WM9 (Met) (2.09 fold) and WM1366 (VGP) (0.9 fold) (Figure 
3.3B).  
 
Figure 3.3A 
 
Figure 3.3B 
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Figure 3.3.  AKAP12 Protein Expression in Human Melanocytes and Melanoma 
Cells.  The amount of AKAP12 protein in control (C) and 10 µM atRA treated 
(R) cells was determined by immunoblotting as described in Materials and 
Methods.  (A)  Immunoblot of AKAP12 protein levels in SbCl2 (RGP), WM1366 
(VGP), and WM9 (Met) human melanoma cells compared to HEMn-LP human 
melanocytes.  Immunoblot of AKAP12 protein levels in WM3211 (RGP), 
WM3248 (VGP), and WM239 (Met) human melanoma cells compared to HEMn-
LP human melanocytes.  (B)  Densitometry of immunoblots (A&B) showing the 
relative changes in AKAP12 protein expression in human melanocytes and 
melanoma cells after 48 hours of atRA treatment.  A value of 1.0 corresponds to 
the level of AKAP12 protein in control cells.  These experiments were repeated 
two additional times with similar results.   
 
     QRT-PCR was used to measure the amount of AKAP12 mRNA in human 
melanocytes and melanoma cells treated +/- 10 µM atRA for 48 hours.  All cell 
lines expressed AKAP12 mRNA and its level was significantly increased relative 
to control in all cell lines after atRA treatment except for WM1366 (Figure 3.4A).  
There was a strong correlation between the degree of atRA induction of AKAP12 
mRNA and protein expression in these cell lines.  Only one cell line (WM3248-
VGP) had basal levels of AKAP12 mRNA that were higher than human 
melanocytes.  The remaining cell lines have the same or significantly lower 
amounts of AKAP12 mRNA relative to normal human melanocytes (Figure 
3.4B). 
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Figure 3.4A 
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Figure 3.4B 
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Figure 3.4.  atRA Stimulation of AKAP12 mRNA Expression in Human 
Melanocytes and Melanoma Cells.  QRT-PCR was performed on total RNA 
extracted from each of the cell lines after 48 hours of +/- 10µM atRA treatment.  
(A)  Changes in AKAP12 expression after atRA treatment.  Data are expressed as 
fold change relative to control cells and normalized using 18S ribosomal RNA 
expression.  (B)  Basal level AKAP12 expression.  Data are expressed as amount 
of AKAP12 mRNA relative to HEMn-LP cells.  Results are the average of 4 
separate experiments.  (∗ = p <0.05, • = p <0.001 compared to control) 
 
Effect of atRA on melanoma cell growth and correlation with 
induction of AKAP12 expression  
     Our laboratory has previously found that atRA inhibits the proliferation of 
mouse and human melanoma cells (Desai and Niles 1997; Huang, et. al., 2002; 
Niles, 2003; Estler, et. al., 2008; Fan, et., al., 2010).  A 72 hour atRA treatment of 
the human melanocyte and melanoma cell lines caused varying amounts of 
inhibition of their proliferation (Table 3.2).  SbCl2 (RGP) cells were the most 
sensitive with a 70% decrease in cell number.  SbCl2 (RGP), HEMn-LP human 
melanocytes, WM3211 (RGP) and WM3248 (VGP) cell proliferation was 
significantly inhibited by atRA.  WM1366 (VGP), WM9 (Met) and WM239 
(Met) melanoma cell proliferation was not significantly inhibited.     
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Table 3.2.  Effect of 72 hours of atRA Treatment on the Proliferation of Human 
Melanocytes and Melanoma Cells.  Cells were seeded, and after a 24 hour growth 
period the media was changed.  Medium contained either DMSO (control) or 10 
µM atRA.  Triplicate dishes from each treatment group were harvested after 24, 
48 and 72 hours of treatment and the number of cells determined by 
hemocytometer counts.  Data are expressed as percent decrease in cell number 
compared to control for each cell line 72 hours after treatment.  (
% = significantly 
different from control; p<0.05)  
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Linear regression analysis revealed that there was a significant correlation 
(p<0.05) between the ability of atRA to inhibit proliferation and its ability to 
increase AKAP12 mRNA levels (Figure 3.5). 
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Figure 3.5.  Linear Regression Analysis of atRA Induced Increase for AKAP12 
mRNA Expression and its Ability to Inhibit Proliferation of the Human 
Melanocyte and Melanoma Cell Lines.  Changes in mRNA expression were 
determined by QRT-PCR and compared to the ability of atRA to inhibit 
proliferation of human melanocytes and melanoma cells.  Data were analyzed 
using the Prism 5 software program.  Analysis shows a statistically significant 
correlation between atRA’s ability to induce AKAP12 expression and its ability to 
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inhibit proliferation, with a slope of 13.65, a p value of 0.0415 and an r2 of 
0.5975.  
 
Induction of AP-1 activity by atRA   
     To understand how AKAP12 gene expression is regulated by atRA we 
conducted an in silico analysis of the AKAP12α promoter region in order to 
identify putative transcription factor binding sites.  This analysis searches highly 
correlated sequence fragments versus TFMATRIX transcription factor binding 
site database by Wingender E, Knueppel R, Dietze P, and Karas H 
(www.cbrc.jp/htbin/nph-tfsearch).  Threshold was set at 85%.  We found three 
putative Activator Protein 1 (AP-1) sites located at positions -3305 (AGCTCA), -
4558 (GAGTCA) and -4879 (AGTTCG) upstream of the AKAP12α start site.  
Previous research in our laboratory has shown that atRA treatment in B16 cells 
induces a slow but sustained increase in AP-1 transcriptional activity (Desai and 
Niles, 1997; Huang, et. al., 2002).  Therefore, it was hypothesized that AP-1 may 
be involved in mediating the atRA induction of AKAP12 gene expression.  
Treatment of B16 mouse melanoma cells, WM3248 (VGP) and WM239 (Met) 
human melanoma cells containing an AP-1 reporter gene with atRA resulted in a 
significant increase in reporter gene activity relative to control treated cells 
(Figure 3.6).  The effect of atRA on AP-1 activity was specific, since adding a 
dominant negative c-fos plasmid (A-fos) to the transfection mixture attenuated 
both basal and atRA stimulated AP-1 activity in all the cell lines (Figure 3.6, 
columns 3&4, 7&8, 11&12). 
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AP-1 Luciferase Activity in A-fos Transfected B16, WM3248 and WM239 
Melanoma Cells Treated with10um atRA
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Figure 3.6.  AP-1 Activity in A-fos Transfected and atRA Treated Melanoma 
Cells.  Luciferase activity was measured in cell lysates that were harvested from 
control and atRA treated B16, WM3248 and WM239 melanoma cells that were 
co-transfected with the β-Gal, AP-1 luciferase vector and either the pCMV 
control vector (columns 1, 2, 5, 6, 9, 10) or the dominant negative c-fos (A-fos) 
vector (columns 3, 4, 7, 8, 11, 12).  Cells were treated for 48 hours with 10 µM 
atRA.  Data is expressed as relative amount of luciferase activity compared to 
control.  Results are the average of 3 separate experiments.  (∗ = p <0.05, • = p 
<0.001 compared to control)  
 
Inhibition of AP-1 activity by the dominant-negative A-fos causes 
a further increase in AKAP12 expression 
     Having shown that the AKAP12 promoter has putative AP-1 binding sites and 
that atRA stimulates AP-1 activity in both mouse and human melanoma cells, we 
tested whether the dominant-negative A-fos would antagonize atRA induction of 
∗ 
• • 
 ∗ 
∗ 
∗ 
• ∗ 
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AKAP12 mRNA levels (Figure 3.7).  Contrary to expectations, A-fos antagonism 
of AP-1 activity enhanced the ability of atRA to increase AKAP12 mRNA levels.  
In A-Fos transfected B16 cells, AKAP12 expression increased from nearly 29 
fold to over 45 fold (an additional 55%).  A-fos expression increased atRA 
stimulated AKAP12 mRNA levels from 6.5 fold to 9 fold (an additional 38%) in 
WM3248 cells, and an additional 43% in WM239 cells.  (Figure 3.7).  These data 
suggest that AP-1 is a negative regulator of AKAP12 mRNA expression. 
 
AKAP12 mRNA Expression in A-fos Transfected B16, WM3248 and 
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Figure 3.7.  AKAP12 mRNA Expression Levels After Down-regulation of AP-1 
Activity.  QRT-PCR was performed on total RNA extracted from Control and 
atRA treated B16, WM3248 and WM239 melanoma cells that were transfected 
with either pCMV control vector (columns 1, 2, 5, 6, 9, 10) or the A-fos plasmid 
(columns 3, 4, 7, 8, 11, 12).  Cells were treated for 48h with 10 µM atRA.  Data is 
expressed as fold change relative to control cells and normalized using 18S 
ribosomal RNA expression.  Results are the average of four separate experiments.    
 ∗ 
 • 
   • • 
∗ ∗ ∗  • 
 - 84 - 
(∗ = p <0.05, • = p <0.001 compared to control)  Statistical analysis was 
performed comparing columns 2&4, 6&8, and 10&12; however, they were not 
statistically significant, most likely due to the variation between the four 
experiments. 
    
Effect of AKAP12 downregulation on invasion in WM3248 
(human) and B16 (mouse) melanoma cells. 
     To determine the effect of AKAP12 down-regulation on WM3248 and B16 
melanoma cell biology, cells were transfected with siRNA to AKAP12 and 
analyzed using CytoSelect Invasion Assay.  These cell lines were used because 
of their high induction of AKAP12 expression after atRA treatment.  Initially, I 
established the amount of AKAP12 RNA and protein down-regulation after 
siRNA transfection in these cell lines.  At 96 hours of transfection with control 
siRNA and AKAP12 siRNA, total RNA and protein was isolated and AKAP12 
levels examined by QRT-PCR and Western blotting.  Figure 3.8 A&B shows that 
in WM3248 cells treated with AKAP12 siRNA there was a 76% decrease in 
mRNA and a 44% decrease in protein expression relative to cells treated with 
control siRNA.  In B16 cells (Figure 3.8 C&D), atRA (1x10-7M) induced a 4.7-
fold increase in AKAP12 mRNA and a 98% increase in protein expression in 
control siRNA transfected cells, while in AKAP12 siRNA transfected cells, 
mRNA expression decreased by 38% and protein levels decreased by 32%.  
However, atRA treatment of AKAP12 siRNA transfected cells still caused a 4.4 
fold increase in AKAP12 mRNA levels compared to control siRNA transfected 
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cells without RA treatment.  Interestingly, treatment of AKAP12 siRNA 
transfected cells treated with atRA resulted in a 51% increase in AKAP12 protein 
compared to control siRNA transfected cells; however, when this is change is 
compared to cells transfected with siRNA to AKAP12, there is a 2.2 fold change 
in protein levels. 
 
Figure 3.8A. 
WM3248 AKAP12 mRNA Levels 96h After 
Transfection with Control and AKAP12 
siRNA 
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Figure 3.8B.                                                                            
AKAP12 Protein Expression in WM3248 Human 
Melanoma Cells after 96h of siRNA Treatment
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Figure 3.8C. 
B16 AKAP12 mRNA Levels 96h After 
Transfection with siCon and siAKAP12
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Figure 3.8D.                                                                           
AKAP12 Protein Expression in B16 Mouse Melanoma 
Cells after 96h of siRNA Treatment
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Figure 3.8.  Ability of AKAP12 siRNA to decrease AKAP12 mRNA and protein.  
WM3248 and B16 cells were transfected with control siRNA and AKAP12 
siRNA for 48h then split, reseeded, and allowed to grow for another 48 hours.  
For B16 cells, appropriate plates of cells were treated with 1x10-7M atRA 6 hours 
after seeding.  After 48h of growth, triplicate plates of cells were harvested for 
RNA and protein measurements.  A representative experiment is shown.  
Experiments were performed a minimum of three times with similar results.  A) 
WM3248 AKAP12 mRNA levels, B) WM3248 protein levels, C) B16 AKAP12 
mRNA levels, D) B16 AKAP12 protein levels.  (∗ = p <0.05, • = p <0.001 
compared to control)   
 
     Next, WM3248 human melanoma cells were assayed for their invasive 
properties.  After 48 hours of transfection with control siRNA and AKAP12 
siRNA to allow for a decrease in the levels of AKAP12 RNA and protein, cells 
were split and reseeded for the invasion assay.  After 48 hours, there was a 44% 
increase in the amount of invasive cells in the AKAP12 siRNA treated cells 
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compared to control siRNA transfected cells (Figure 3.9A).  Images clearly show 
the increase in invasive cells.  Figure 3.9B shows the amount of invasive cells in 
the control siRNA transfected cells, while figure 3.9C shows the amount of 
invasive cells in siAKAP12 transfected cells. 
 
Figure 3.9A. 
48h Invasion Assay on WM3248 Human Melanoma Cells 
(96h siRNA Transfection)
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Figure 3.9.  Effect of decreasing AKAP12 levels on invasion in WM3248 human 
melanoma cells.  Cells were transfected with control siRNA and AKAP12 siRNA 
for 48h, then split and reseeded into triplicate sets of wells for the CytoSelect 
Invasion assay, which was performed according to manufacturer’s protocol.  At 
48 hours of incubation, invasive cells were photographed, harvested and counted.  
A representative experiment is shown.  These experiments were repeated a 
minimum of three times with similar results.  A) Relative number of invasive cells 
expressed as a percent of cells transfected with control siRNA B) Image of 
WM3248 cells transfected with siControl, C) Image of WM3248 cells transfected 
with siAKAP12.  (∗ = p <0.05 compared to control) 
 
     Next, the effect of decreasing AKAP12 expression on the invasive properties 
of B16 melanoma cells was determined.  Cells were transfected with control 
siRNA or AKAP12 siRNA 48h before reseeding the cells into the invasion assay.  
Treatment of cells transfected with control siRNA plus atRA had a 37% decrease 
in the number of invasive cells compared to control siRNA transfected cells 
receiving vehicle (Figure 3.10A).  However, when AKAP12 levels were 
decreased due to transfection with AKAP12 siRNA, there was a 28% increase in 
the amount of invasive cells relative to control siRNA transfected cells.  In 
siAKAP12 transfected cells treated with atRA, there was a 19% decrease in the 
number of invasive cells compared to control siRNA transfected cells.  
Comparing control siRNA transfected cells treated with atRA to AKAP12 siRNA 
transfected cells treated with atRA there were 18% more invasive cells when 
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AKAP12 levels are decreased.  Photographic images also show the change in the 
amount of invasive B16 cells.  The image in Figure 3.10B shows the amount of 
invasive cells after transfection with control siRNA, Figure 3.10C is an image of 
the invasive cells after transfection with control siRNA and treatment with 1x10-
7M atRA.  Note the reduced number of invasive cells.  Figure 3.10D is an image 
of invasive cells after transfection with siAKAP12, note the larger number 
compared to image B.  Figure 3.10E is an image of invasive cells after 
transfection with siAKAP12 and treatment with 1x10-7M atRA. 
 
 
 
Figure 3.10A. 
48h Invasion Assay on B16 Mouse Melanoma Cells (96h 
siRNA Transfection)
100
63
128
81
0
20
40
60
80
100
120
140
siControl siC+RA siAKAP12 siA+RAA
m
ou
nt
 o
f I
nv
as
iv
e 
Ce
lls
 R
ep
re
se
nt
ed
 
as
 %
 o
f C
on
tro
l
 
 
 
 
 
 ∗ 
   ∗ 
∗ 
 - 91 - 
B. siControl transfected B16 cells          C. siControl transfected B16 cells + RA  
 
 
D. siAKAP12 transfected B16 cells     E. siAKAP12 transfected B16 cells + RA 
 
 
Figure 3.10.  Effect of decreased AKAP12 levels on B16 mouse melanoma cells.  
B16 cells were transfected with control siRNA or AKAP12 siRNA for 48h, then 
split and reseeded into triplicate wells of the CytoSelect Invasion Assay, which 
was performed according to manufacturer’s protocol.  Control samples were 
treated with DMSO and RA treated samples received 1x10-7M atRA.  After 48 
hours, invasive cells were photographed, harvested and enumerated.  A 
representative experiment is shown.  Experiments were repeated a minimum of 
three times with similar results.  A) Number of invasive cells relative to control, 
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B) cells transfected with control siRNA, C), cells transfected with control siRNA 
then treated with 1x10-7M atRA, D) cells transfected with AKAP12 siRNA, E) 
cells transfected with AKAP12 siRNA then treated with 1x10-7M atRA.  (∗ = p 
<0.05 compared to control) 
 
Effect of AKAP12 downregulation on anchorage-independent 
growth in B16 mouse melanoma cells. 
     B16 cells were used to investigate the potential involvement of AKAP12 in 
regulating anchorage-independent growth due to their atRA sensitivity and their 
ability to form numerous colonies quickly in soft agar.  WM3248 human 
melanoma cells were not used for this assay because they are unable to form 
colonies until at least 7 days after the start of the assay, a time at which the effect 
of AKAP12 siRNA was lost.  Anchorage-independent growth was measured 
using the Cyto-Select 96-Well Cell Transformation Assay.  B16 cells were 
transfected with control siRNA and AKAP12 siRNA for 48 hours before 
reseeding into the transformation assay.  At 48 hours of incubation in this assay 
there was a 31% decrease in colony formation in cells transfected with control 
siRNA plus treatment with 1x10-7M atRA relative to cells transfected with control 
siRNA, but not treated with atRA (Figure 3.11A).  In cells transfected with 
AKAP12 siRNA, colony formation increases 70% compared to cells transfected 
with control siRNA.  The cells transfected with AKAP12 siRNA and then treated 
with 1x10-7M atRA had a similar amount of anchorage-independent growth 
relative to control siRNA transfected cells.  Photographic images show the 
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changes in soft agar colony formation.  Figure 3.11B is an image of colony 
formation in control siRNA transfected cells and Figure 3.11C is an image of 
colony formation after transfection of control siRNA and a 48h treatment with 
1x10-7M atRA.  Note the reduced number and smaller colonies.  Figure 3.11D is 
an image of colony formation after 48h transfection with AKAP12 siRNA.  This 
image shows larger and more abundant colony formation.  Figure 3.11E is an 
image of colony formation in AKAP12 siRNA transfected cells and treated for 
48h with 1x10-7M atRA.  This image verifies that colony formation is still 
reduced in these cells. 
 
Figure 3.11A. 
48h Anchorage-Independent Growth Assay on B16 
Mouse Melanoma Cells (96h siRNA Transfection)
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B. siControl transfected B16 cells          C. siControl transfected B16 cells + RA 
 
 
D. siAKAP12 transfected B16 cells      E. siAKAP12 transfected B16 cells + RA 
 
Figure 3.11.  Effect of decreased levels of AKAP12 on anchorage-independent 
growth.  B16 cells were transfected with control siRNA and AKAP12 siRNA for 
48h, then split and reseeded into triplicate wells for the CytoSelect  96-Well 
Cell Transformation Assay, performed according to manufacturer’s protocol.  
Control transfected siRNA cells and AKAP12 siRNA transfected cells received 
either DMSO or 1x10-7M atRA.  After 48h of growth, cells were photographed, 
harvested and assayed for anchorage-independent growth.  A representative 
experiment is shown.  Experiments were repeated a minimum of three times.  
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Each repeat contained a minimum of 3 sample repeats per assay.  A)  Amount of 
soft agar colony growth relative to control cells, B) cells transfected with control 
siRNA, C) cells transfected with control siRNA and treated with 1x10-7M atRA, 
D) cells transfected with AKAP12 siRNA, E) cells transfected with AKAP12 
siRNA and treated with 1x10-7M atRA.  (∗ = p <0.05 compared to control) 
 
 
     We also examined anchorage-independent colony formation after 72 hours of 
incubation (120 hours after transfection with control siRNA and AKAP12 
siRNA).  Cells transfected with control siRNA and treated with 1x10-7M atRA for 
72 hours still showed a 40% decrease in colony formation (Figure 3.11A).  In 
AKP12 siRNA transfected cells, colony formation was only increased by 25% 
(Figure 3.12A), while a 72 hours treatment of AKAP12 siRNA transfected cells 
with 1x10-7M atRA causes a 28% decrease in colony formation, compared to cells 
transfected with control siRNA.  However, if this change is compared to what is 
seen in AKAP12 siRNA transfected cells, the decrease in colony formation is 
58%, which is a greater decrease than what is seen in control siRNA transfected 
cells treated with atRA. 
     We also examined RNA and protein levels in B16 cells 120 hours after 
transfection with control siRNA or AKAP12 siRNA.  QRT-PCR analysis shows 
that after 72 hours of 1x10-7M atRA treatment in control siRNA transfected cells 
there is a 9.62 fold induction of AKAP12 mRNA (Figure 3.12B).  Cells 
transfected with AKAP12 siRNA show only a 22% decrease in AKAP12 mRNA 
relative to cells receiving control siRNA, indicating that the siRNA is losing its 
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effect.  However, AKAP12 siRNA transfected cells treated with 1x10-7M atRA 
had a 5.93 fold increase in AKAP12 mRNA, a reduction of almost 3.7 fold 
relative to control cells treated with atRA.  Western blot analysis of protein levels 
show that while mRNA levels are very high in siControl+atRA treated cells, 
protein levels are only increased 60%.  In cells transfected with AKAP12 siRNA 
there is surprisingly an increase in AKAP12 protein relative to control siRNA 
transfected cells (49%) (Figure 3.12C).  Even though atRA could only increase 
AKAP12 protein levels by 60% in control cells, in cells receiving AKAP12 
siRNA prior to atRA treatment there is a 3.1 fold increase in AKAP12 protein 
levels.     
 
Figure 3.12A.  
B16 Mouse Melanoma Cells - 72h Anchorage-
Independent Growth Assay
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Figure 3.12B. 
B16 AKAP12 mRNA Levels 120h After 
Transfection with siCon and siAKAP12
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Figure 3.12C.                            
AKAP12 Protein Expression in B16 Mouse Melanoma 
Cells after 120h of siRNA Treatment
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Figure 3.12.  Effect of AKAP12 siRNA treatment on B16 mouse melanoma 
anchorage-independent growth 72 hours after treatment (mRNA and protein 
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levels are also included).  B16 cells were transfected with control siRNA or 
AKAP12 siRNA for 72 hours, then split and reseeded into triplicate wells per 
treatment group for the CytoSelect 96-Well Cell Transformation Assay, which 
was performed according to manufacturer’s protocol.  Cells were treated with 
DMSO or 1x10-7M atRA.  After 72h of growth, cells were photographed, 
harvested and assayed for anchorage-independent growth.  A representative assay 
is shown.  The experiment was repeated two additional times with similar results.  
A) 72hour anchorage-independent growth assay, B) AKAP12 mRNA levels 120 
hours after transfection, C) AKAP12 protein levels 120 hours after transfection.  
(∗ = p <0.05, • = p <0.001 compared to control)   
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Discussion 
 
 
     Cutaneous malignant melanoma (CMM) is the most serious form of skin 
cancer and its incidence is steadily increasing.  The ability of retinoids to regulate 
melanoma cell growth and differentiation has been well documented, yet research 
has also shown that as melanoma progresses from RGP to VGP to Met, cells lose 
their responsiveness to atRA (Jacob, et. al., 1998; Niles, et. al., 2003; Fan, et. al., 
2010).  We lack a complete understanding as to how atRA exerts its anti-cancer 
effects and don’t fully understand why advanced stage melanomas become so 
resistant to the effects of atRA.  
     Gene expression profiling using DNA microarrays was performed on control 
and atRA treated B16 mouse melanoma cells to help discover new target genes of 
atRA.  We identified AKAP12 as a novel, atRA target gene.          
          AKAP12 is an anchoring protein that is involved in assembly and 
compartmentalization of multi-protein complexes, thus coordinating and directing 
the transduction of multiple signaling pathways.  The development and 
progression of CMM involves many molecular and genetic changes affecting 
multiple signaling pathways that regulate growth, metabolism, motility and 
apoptosis.  AKAP12 may play a pivotal role in regulating these changes as it lies 
at a central junction where the regulation of these pathways converges.  However, 
the role of AKAP12 in the function of melanocyte and melanoma biology is 
currently not known.    
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     AKAP12/Gravin/SSeCKS is believed to be a Type II tumor suppressor gene, 
because its protein and RNA expression are downregulated in many epithelial 
derived tumors, and its re-expression in cancer cells has been demonstrated to 
suppress various parameters of tumor function.  Research from Dr. Irwin 
Gelman’s laboratory has shown that over-expression of AKAP12/SSeCKS in 
NIH3T3 cells causes inhibition of cell growth by promoting G1 phase arrest 
through binding and regulation of cyclin D activity (Gelman, 2002; Lin, et. al., 
2000).  It also promotes re-organization of the actin-based cytoskeleton and 
induces cell flattening (Nelson and Gelman, 1997; Gelman, et. al., 1998; Gelman, 
et. al., 2000; Xia and Gelman, 2002; Cheng, et. al., 2007).  In addition, ectopic 
AKAP12 expression inhibits podosome formation and metastatic progression in 
human prostatic cancer (Lin and Gelman, 1997; Xia, et. al., 2001; Gao and 
Gelman, 2006).  The AKAP12 gene locus on chromosome 6 contains a deletion 
hotspot and aberrations on chromosome 6 are important in CMM progression.  
Vertical growth phase and metastatic melanomas also have nonrandom 
abnormalities on chromosome 6 (Liotta, et. al., 1987).  These observations 
suggest that AKAP12 may play a role in melanoma progression. 
     There are only two published reports that have examined AKAP12 expression 
in melanoma cells.  Hacker et al (2008) compared spontaneous vs UVR-induced 
mouse melanoma.  There were 264 genes differentially expressed between these 
two groups.  qRT-PCR verified that AKAP12 expression was downregulated in 
the UVR-induced mouse melanomas.  In the second report, 5-aza-2-
deoxycytidine, a DNA methylation inhibitor and trichostatin A, an inhibitor of 
 - 101 - 
histone deacetylase were used to determine genes that were reactivated in 
melanoma cell lines (Bonazzi, et. al., 2009).  Although AKAP12 was one of these 
genes, its re-expression did not correlate with a high proportion of promoter 
demethylation. 
       Recently Streb et al (2011) found that atRA stimulates AKAP12 expression 
in vascular smooth muscle cells.  In this study, atRA specifically targeted the 
induction of the AKAP12β isoform.  Based upon an early induction of the 
AKAP12 mRNA (3h) and the presence of a RARE in the promoter of AKAP12, it 
was concluded that AKAP12β is a retinoid responsive immediate-early gene.  
This finding is in contrast to our results in melanoma cells, where AKAP12 
expression was not induced until 24 hours after atRA treatment and no RARE’s 
were identified in the AKAP12α promoter region.             
     The induction of AKAP12 by atRA is significantly correlated with the ability 
of this retinoid to inhibit melanoma cell proliferation.  There is limited 
information on the ability of AKAP12 to regulate proliferation in various cancer 
cell lines.  However, several studies suggest that it plays an important role in other 
aspects of tumor biology, such as cancer cell invasiveness and metastatic 
properties (Lin and Gelman, 1997; Gao and Gelman, 2006; Su, et. al., 2010).  
Failure of atRA to increase AKAP12 expression is associated with an inability to 
inhibit melanoma cell growth.  Although these data suggest that high levels of 
AKAP12 may also mediate atRA induced growth inhibition of melanoma cells, 
some cell lines such as WM3248 can be induced by atRA to produce high levels 
of AKAP12, but are relatively unaffected by the growth inhibitory effects of 
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atRA.  One possibility for this anomaly is that the retinoic acid nuclear receptor 
that mediates the induction of AKAP12 expression is different from the one that 
mediates inhibition of proliferation.   
     To address how atRA was inducing the expression of AKAP12, I performed a 
computer analysis of transcription factor binding sites within the AKAP12 
promoter.  While I did not find any RARE site, I did identify several putative AP-
1 sites.  Since our laboratory previously reported that atRA increases AP-1 
activity in mouse melanoma cells (Desai and Niles, 1997; Huang, et. al., 2002), I 
tested the hypothesis that atRA was increasing AKAP12 mRNA expression 
through its ability to stimulate AP-1 activity.  AP-1 activity was increased in 
several of our human melanoma cell lines when treated with atRA.  This finding 
reproduces what we previously reported in B16 melanoma cells.   
     I tested whether AP-1 mediates the atRA induction of AKAP12 in B16 cells by 
inhibiting AP-1 activity through the use of the dominant negative fos (A-fos).  
The role of AP-1 in the regulation of AKAP12 expression in melanoma is 
opposite to what we had hypothesized.  Instead of mediating the increase in 
AKAP12 in atRA-mediated melanoma cells, AP-1 acts as a negative regulator.  
This conclusion is based on the findings that inhibition of AP-1 activity through 
expression of a dominant-negative A-fos plasmid led to a higher degree of atRA-
induced AKAP12 stimulation compared to cells with normal AP-1 activity.  This 
negative regulation of AKAP12 expression by AP-1 may be explained by the 
location of its binding sites.  The AKAP12 promoter can be subdivided into three 
sections that contain a basal promoter region (-173 to +1), a modulator region (-
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588 to -174) and a negative control region (-4764 to -589) (Streb 2004).  My in 
silico analysis of the AKAP12 promoter revealed that the putative AP-1 binding 
sites lie within the negative regulatory region (-4764 to -589).  I postulated that 
specific deletion or mutation of these sites will lead to enhanced stimulation of 
AKAP12 expression by atRA.   
     This paradox of atRA-induced increase of a negative regulator of AKAP12 
expression suggests that very high levels of AKAP12 might be detrimental to its 
normal functioning in the regulation of signaling processes.  I hypothesized that if 
cellular AKAP12 levels remain too low, this may predispose the cell to an 
enhanced proliferative state, augmenting the loss of controls on processes such as 
cell adhesion and motility.  In contrast, if AKAP12 levels are too high, signaling 
molecules such as protein kinases are tightly sequestered by the AKAP12 
scaffold, thus preventing the normal functioning of pathways.  If this latter 
situation is not reversed it could lead to cell death.    
     Epigenetic factors are also involved in the control of AKAP12 expression.  
Methylation of the AKAP12 promoter has been described and associated with 
silenced or reduced expression of AKAP12 mRNA (Jin, et. al., 2008; Mardin, et. 
al., 2010).  This mechanism may explain the lack of AKAP12 induction in 
response to atRA treatment seen in WM1366 (VGP) melanoma cells. 
     Because AKAP12 is a “late” atRA regulated gene and does not contain any 
discernable retinoic acid response elements, it is likely that an “early” atRA 
directly-regulated gene is responsible for the stimulation of AKAP12 mRNA and 
subsequently protein levels in mouse and human melanoma cells.  My current 
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working model for atRA regulation of AKAP12 is shown in Figure 13.  In the 
unstimulated state, there is basal expression of the AKAP12 gene and AP-1 may 
be bound to some of its consensus sequences.  Upon addition of atRA, the RAR 
(retinoic acid receptor): RXR (retinoid X receptor) heterodimer complex is 
activated and stimulates the expression of gene “X”.  In addition, atRA stimulates 
increased AP-1 activity.  The expression of Gene “X” increases and binds to its 
consensus sequence, most likely located in the basal promoter region or the 
modulator region of the AKAP12 gene.  While the binding of factor “X” induces 
transcriptional activity of the AKAP12 gene, the binding of AP-1 works to repress 
expression, restraining the overall production of AKAP12 mRNA and protein.  
 
 - 105 - 
 
 
Figure 13.  Working model for atRA induction of AKAP12 gene activity in 
melanoma cells.  This diagram shows the promoter region of the AKAP12α gene.  
A is the basal promoter region, B is the modulator region and C is the negative 
control region.  Numbers indicate the location of the AP-1 DNA binding sites.  
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After addition of atRA, the activated RAR/RXR heterodimer binds to the retinoic 
acid response element located in Gene X and induces its expression.  In addition, 
atRA also stimulates increased activity of the transcription factor AP-1.  Gene X 
may bind to a site located in the basal promoter or modulator region to induce the 
expression of AKAP12.  However, the increased activity and subsequent binding 
of AP-1 to the regions located in the negative control region modulates the overall 
level of AKAP12 expression.    
 
     To ascertain AKAP12 function in melanoma cell biology, WM3248 (human) 
and B16 (mouse) melanoma cells were transfected with siRNA to AKAP12 in 
order to decrease its expression.  These treated cells and appropriate controls were 
assayed for their ability to invade Matrigel basement membranes and grow in an 
anchorage-independent manner.    AKAP12/SSeCKS/Gravin re-expression has 
been shown to inhibit Matrigel invasion and soft agar colony formation in NIH-
3T3 fibroblasts and MLL prostate cancer cells (Lin 1997, Gao 2006, Su 2010).  
The effect of AKAP12’s decreased expression on atRA’s ability to regulate 
melanoma cell invasion and proliferation was also examined.  AKAP12 knock-
down in non-atRA treated WM3248 and B16 cells results in increased invasive 
properties.  AKAP12 knock-down also increased anchorage-independent growth 
in B16 melanoma cells.  Although atRA treatment inhibits invasion and soft agar 
colony formation in B16 cells, and the down-regulation of AKAP12 expression 
does somewhat antagonize the ability of atRA to inhibit invasive and proliferative 
properties, results were not as significant as we expected.  One possibility to 
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explain these findings is the amount of time (4-5 days after siRNA transfection) 
required to measure anchorage-independent growth.  This prolonged time leads to 
decreased capacity of the siRNA to downregulate AKAP12 expression, allowing 
atRA to overcome the effects of the silencing RNA. 
      It would be interesting to determine the biological effect of over-expressing 
AKAP12 in melanoma cells, such as WM1366, which are unresponsive to the 
effects of atRA and exhibit only low levels of AKAP12 induction after atRA 
treatment.  Overexpression of AKAP12 was attempted using two different 
plasmids; pEGFP-Gravin and pcDNA3.1/V5/His-Gravin.  These plasmids were 
submitted to us by Dr Bryon Grove, at the University of North Dakota, School of 
Medicine.  The vectors were 4.7 and 5.4kb respectively, while the Gravin insert 
was 5.343kb.  Due to the large size of the Gravin insert, I found it very difficult to 
achieve a reasonable amount of expression in any of the melanoma cell lines 
tested with these plasmids.           
     In conclusion, I have demonstrated that atRA regulates the expression of 
AKAP12 in mouse melanoma and in human melanocytes, and to varying degrees, 
human melanoma cells.  Further, the induction of AKAP12 is tightly linked to 
inhibition of melanoma cell proliferation by atRA.  However, additional 
experiments are needed in order to understand how AKAP12 expression is being 
regulated.  My studies also suggest that AKAP12 has a tumor suppressive role in 
melanoma biology, regulating metastatic and proliferative properties of melanoma 
cells.  
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Chapter 4: Conclusion 
     During the process of melanoma tumor growth and progression, many genes 
become deregulated and contribute to its lethality.  The regulation of gene 
expression requires a complex network of positive and negative growth factors, 
signaling pathways, and transcription factors.  Transcriptional regulation of genes 
in melanoma is a multifaceted process that over-rides the normal melanocyte 
signaling pathways and there is a powerful association between signal 
transduction pathways and the activation of transcription factors that are involved 
in coordinating gene transcription.  Transcription factors play a fundamental role 
in controlling the activity of genes that regulate physiological functions such as 
cell growth, survival, apoptosis, energy metabolism, inflammation, 
differentiation, invasion, and metastasis in melanoma cells (Poser and Bosserhoff, 
2004). 
     To help identify the key regulatory factors that contribute to melanoma 
aggressiveness, a comparative analysis of gene expression data sets from the 
NCBI GEO database using melanoma, basal cell carcinoma and seven other 
cancer types was performed.  In this analysis, advanced VGP melanoma had the 
highest number of differentially expressed genes (Xu, et. al., 2012).  There is also 
an upregulation of key genes involved in fatty acid metabolism (β-oxidation), cell 
invasion and metastasis. 
      Although available technology can identify the changes in gene expression 
taking place during melanoma progression, as well as during specific treatment 
protocols, it is important to address the cause of these gene expression changes.  
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Because transcription factors are major players in this mechanism, we need to 
know what role they play in altering the expression of targeted genes during the 
progression of melanoma.  
     My research centered on the activity of two transcription factors that regulate 
key genes involved in melanoma progression.  They are members of a super-
family of ligand-activated transcription factors that include the RAR’s, RXR’s, 
PPAR’s, LXR’s, FXR’s, thyroid receptor and Vitamin D receptor.  The first part 
of my thesis work investigated the biological effect of PPARα/γ activation in B16 
mouse melanoma cells, and the second part examined the expression and function 
of an indirect target gene of RAR activation, AKAP12.  Both PPARs and RARs 
induce gene activity through a similar mechanism and have been shown to 
regulate the expression of genes involved in cell growth and differentiation.  
     PPARs are transcription factors that regulate genes involved in glucose and 
fatty acid metabolism.  They also regulate pathways controlling cellular 
proliferation, differentiation, tumor promotion, apoptosis and the immune 
response.  Ligands that activate PPARs have chemoprevention effects and inhibit 
growth in several different types of cancer cells (Sertznig, et. al., 2007; Sertznig, 
et. al., 2010).  I therefore investigated the role of PPARs in regulating melanoma 
cell growth.       
     The results of my experiments show that B16 mouse melanoma cells have 
increased expression of PPARα and γ protein, but the growth of melanoma cells 
treated with PPAR agonists was only moderately inhibited and PPARγ agonists 
were more effective at inhibiting proliferation than PPARα agonists.  In addition, 
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there is some problem with detecting the ability of PPARs to initiate gene 
transcription.  I was not able to detect a measurable level (lack of reporter gene 
activity) of endogenous receptor, indicating that there is some problem with 
regulating the expression of target genes.  This decrease in transcriptional activity 
might be due to the constitutive activation of the mitogen-activated kinase 
pathway, inducing phosphorylation of specific serines by ERK1/2, located in the 
N-terminal ligand-independent activation domain of the PPARs.  This 
phosphorylation induces a conformational change in the protein that hinders its 
ligand binding ability and downregulates its activity.  The reason for this level of 
regulation could be due to PPARs ability to activate the expression of genes 
involved in inhibition of the cell cycle.  More investigation is needed to determine 
how alteration in PPARs may contribute to melanoma proliferation.  
Unfortunately, there are few new articles that have addressed the issue of PPAR 
function in melanoma since the publication of our work.  
     There are reports of PPAR agonists having effects on metastatic properties and 
tumor proliferation.  Grabacka M, et.al., (2006), demonstrated that activation of 
PPARα with fenofibrate inhibited mouse and human melanoma cell invasion and 
soft agar growth.  Also, in mouse xenograft models of melanoma, mice were 
given either the PPARγ agonist rosiglitazone; a RXR agonist; or a combination of 
the two.  Melanoma tumor growth was significantly inhibited by either ligand 
alone and the combination had an additive effect (Klopper, et. al., 2009).  These 
results show that PPARγ agonists can still be effective inhibitors of melanoma 
cell proliferation. 
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     For the second part of this project, my research was focused on a newly 
identified indirect target gene of RAR activation that had not been previously 
examined in melanoma cells.  This gene, AKAP12, has been characterized in 
other cancer cell lines, especially prostate (Xia, et. al.,2001), as being a major 
regulator of signal transduction pathways that control cell adhesion and oncogenic 
growth through its binding and sequestering of many different second 
messengers.  Currently, there are no publications reporting the atRA regulation of 
AKAP12 expression in melanoma cells, or that address its role in melanoma cell 
biology. 
     The majority of information on AKAP12 and cancer has come from work done 
by Dr. Irwin Gelman’s laboratory at the Roswell Park Cancer Institute, through 
the use of fibroblasts and prostate cancer cell lines.  In Ras-transformed NIH3T3 
fibroblasts, downregulation of SSeCKS increased soft agar colony formation and 
Matrigel invasiveness (Lin and Gelman, 1997).  Re-expression of SSeCKS in 
MLL prostate cancer cells suppresses formation of lung metastasis and suppresses 
the expression of vascular endothelial growth factor (VEGF), hypoxia-inducible 
factor-1α (HIF-1α), and platelet-derived growth factor receptor β (PDGFRβ).  
SSeCKS was shown to suppress the formation of metastatic lesions through 
inhibition of VEGF expression and induction of soluble anti-angiogenic factors.  
This inhibits neovascular formation induced by tumor cells at peripheral sites (Su, 
et. al., 2006).  SSeCKS-knockout mice develop prostate hyperplasia, suggesting 
that these mice have increased susceptibility for oncogenic transformation 
(Akakura, et. al.,2008).  In nude mice injected with MLL cells containing a 
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tetracycline regulated SSeCKS expression vector, re-expression severely 
decreased the formation of secondary lung metastasis, indicating that loss of 
SSeCKS plays a major role in the metastatic progression of human prostate cancer 
cells (Xia, et. al., 2001).  In addition, the re-expression of SSeCKS in NIH3T3 
cells suppresses podosome formation and decreases Matrigel invasiveness.  
Pososomes are actin-rich structures commonly found in cancer cell lines and are 
believed to assist in the invasive properties involved in metastasis of tumor cells.  
SSeCKS aids in the suppression of oncogenisis by re-establishing the normal 
actin-based cytoskeletal architecture (Gelman and Gao, 2006).         
     My research shows that, not only do mouse and human melanoma cells 
express AKAP12, its expression is regulated by atRA.  During my research on 
AKAP12, I also made a novel finding that the transcription factor AP-1 is a 
negative regulator of AKAP12 expression.  Functional assays for quantifying the 
invasive and anchorage-independent growth properties of mouse and human 
melanoma cells showed that when AKAP12 expression was decreased, invasion 
and soft agar colony formation was significantly increased.  However, knockdown 
of AKAP12 in melanoma cells treated with atRA only partially antagonized the 
ability of this retinoid to inhibit Matrigel invasion and soft agar colony formation.  
The AKAP12 siRNA could not sufficiently decrease the strong atRA induction of 
AKAP12 enough to establish if there were changes in Matrigel invasion and 
anchorage-independent growth.  Therefore, it is still possible that atRA inhibits 
these melanoma activities through other mechanisms in addition to stimulating the 
expression of AKAP12.  I hypothesize that AKAP12 may play a tumor 
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suppressive role in melanoma biology through coordinating signaling pathways 
that prevent metastasis and anchorage-independent growth. 
     The ability of AKAP12 to regulate these various pathways stems from its 
function as a scaffolding protein.  This protein works to sequester and inhibit the 
activity of many different enzymes, including those involved in transducing 
signals through the cytoplasm of cells, events commonly initiated at the cell 
membrane.  The ability of AKAP12/SSeCKS/Gravin to associate with both the 
plasma membrane and the actin cytoskeleton places this protein at a position 
where it can have direct control over regulating the activity of various signaling 
pathways and the actin based cytoskeletal architecture.  Many of these pathways 
regulate proliferation, differentiation, survival and metastatic properties (Gelman, 
2002).  
 
 
Figure 4.1  Model for AKAP12 scaffolding functions.  During G0 or the early G1 
phase of the cell cycle, the AKAP12 protein sequesters key signaling proteins 
such as PKA, PKC, calmodulin (CaM), phosphatase 2B (PP2B), and cyclin D 
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(CyD).  After mitogenic stimuli, AKAP12 is rapidly phosphorylated by PKC, 
inducing a conformational change that leads to the release of the various enzymes 
and translocation of AKAP12 to the endoplasmic reticulum (ER) in peri-nuclear 
area.  This process leaves all of the enzymes free to become active themselves and 
to regulate the activities of a variety of their substrates.  The change in AKAP12s 
ability to interact with actin, as well as its various binding proteins, enable the cell 
to undergo changes in shape more easily (formation of podosome), which is 
necessary for invasion and metastasis. 
  
    Most melanoma cells harbor mutated proteins, such as NRAS and BRAF, that 
constitutively activate the MAPK pathway.  Evidence suggests a link between the 
MAPK pathway, the ability of AKAP12/SSeCKS to bind and regulate the activity 
of protein kinase C (PKC), and cancer cell invasiveness (Su, et. al., 2010).  PKC 
is a serine/threonine protein kinase that plays a role in regulating many cellular 
functions including cell growth and differentiation.  AKAP12 suppresses 
metastatic motility in MAT-LyLu (MLL) prostate cancer cells by inhibition of the 
RAS/RAF/MEK/ERK1/2 pathway through direct binding of PKC (Su, et. al., 
2010).  Re-expression of SSeCKS in MLL cells causes a 50-65% decrease in total 
PKCα activity, yet there is no change in total PKCα expression.  This is 
interesting, because our laboratory has previously shown that RA induces a 6-8 
fold induction of PKCα mRNA and protein, and a 4-fold induction of AP-1 
activity (Desai and Niles, 1997; Huang, et. al., 2002).  In addition, only the PKCα 
protein, but not enzyme activity, was required for the RA-induced AP-1 activity 
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seen in live melanoma cells.  The atRA stimulation of AP-1 activity contributes to 
growth arrest and differentiation.  Treatment of B16 mouse melanoma cells with 
the PKC enzyme inhibitor bisindoylmaleimide did not block the RA response 
(Desai and Niles, 1997).  Also, over-expression of PKCα in these cells resulted in 
a more differentiated phenotype (Gruber, et. al., 1992).  From this information 
and my investigation of AKAP12 expression and function, I suggest that the 
increase in AKAP12 expression seen in RA treated melanoma cells is coupled to 
an increase in PKCα expression.   This increase in PKCα protein expression seen 
in melanoma cells may be necessary for AKAP12’s normal functioning as a 
scaffolding protein.  PKCα activity is not needed because AKAP12 is able to bind 
and block its ability to function as a kinase protein.  
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Figure 4.2.  Model of AKAP12 scaffolding function in melanoma cells before 
and after treatment with atRA.  In melanoma cancer cells, there are decreased 
levels of AKAP12 protein.  Also, these cells are highly proliferative, with a higher 
fraction of cells in the G2/S phase of the cell cycle relative to normal 
melanocytes.  The AKAP12 protein becomes positioned at the (endoplasmic 
reticulum) ER near the nucleus of the cell, not at the cell membrane where it 
would normally be located.  The protein Cyclin D (CyD) has also translocated to 
the nucleus, because of its involvement in cell cycle progression.  The enzymes 
PKA, PKC, CaM, and PP2B, are free to become active, regulating the activity of 
their substrate proteins, and in turn the activity of various signaling pathways.  
Retinoic acid works to inhibit melanoma cell growth by first halting proliferation 
at the G1 phase of the cell cycle.  It is also responsible for increased expression 
levels of the proteins PKC and AKAP12 (as an indirect target gene), and for 
increased activity of the transcription factor AP-1.  As the cells halt their 
proliferation at G1, cyclin D translocates from the nucleus to the cell membrane to 
become bound to AKAP12.  PKC protein levels also increase, similar to those of 
AKAP12.  The docking of PKC to the AKAP12 scaffolding protein is essential 
for the ability of AKAP12 to bind all of the appropriate proteins in the correct 
conformation.  The re-localization of cyclin D and increased PKC protein levels, 
combined with increased AKAP12 protein, allow AKAP12 to function as a 
negative mitogenic regulator, sequestering and inhibiting the enzymatic properties 
of the various proteins.    
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       PKC can also influence RA signaling by altering the stability of the RARα 
protein.  Activation of PKC in mouse melanoma cells leads to an increase RARα 
protein levels, while downregulation of PKC diminishes RARα protein half-life 
and markedly inhibits ligand-independent transcriptional activity (Boskovic, et. 
al., 2002).  Regulation of RARα expression and activity may be one possible way 
of influencing the RA-induced expression of AKAP12.  
     Another possible mechanism for AKAP12 regulation of the melanoma 
phenotype is though its ability to regulate G-protein coupled receptor (GPCR) 
activity (Shih, et. al., 1999).  The melanocortin-1 receptor (MC1R) is a G-protein 
coupled receptor that is involved in melanoma function and development.  
Individuals with mutations in this receptor produce more of the red/yellow 
pigment pheomelanin, than the black photo-protective pigment eumelanin.  
Because of the decreased eumelanin expression, these individuals usually have 
fair skin and light colored hair, and are more sensitive to UV induced DNA 
damage.  Stimulation of GPCRs involves phosphorylation of the receptor, which 
is a critical element of agonist-induced desensitization, leading to internalization 
of the receptor for recycling.  This process includes the involvement of the 
enzymes PKA, G protein-coupled receptor kinases (GRKs) and the adaptor 
molecule β-arrestin.  The activity of MC1R is regulated by the agonists ACTH 
(adrenocorticotropic hormone) and αMSH (melanocyte stimulating hormone), 
while ASIP (agouti signaling peptide) is an antagonist.  Receptor activation 
induces the activity of adenylate cyclase, resulting in increased production of 
cAMP.  This cyclic nucleotide is necessary for PKA activation.  AKAP12 not 
 - 124 - 
only binds the kinases PKA and PKC, as well as phophatase 2B (PP2B), but can 
also directly associate with the GPCR.  The physical association of AKAP12 to 
the β2-GPCR affects signaling through regulation of agonist-induced 
desensitization of the receptor.  The protein phosphatase PP2B plays a critical role 
in resensitization due to its ability to dephosphorylate the receptor (Shih, et. al., 
1999).  Once desensitization and internalization of the MC1R is complete, 
AKAP12 plays a crucial role in resensitization (dephosphorylation) and recycling 
of the receptors back to the cell membrane.  Therefore, the reduced AKAP12 
expression in melanoma cancer cells may influence and downregulate MC1R 
activity, by impeding recovery from agonist-induced desensitization (Shih, et. al., 
1999; Tao, et. al., 2007; Tao and Malbon, 2008). 
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Figure 4.3.  Model for the regulation of melanocortin 1 receptor (MC1R) 
signaling by AKAP12.  AKAP12 provides docking sites for protein kinase A 
(PKA), protein kinase C (PKC), and phosphatase 2B (PP2B) and many other 
enzymes and adaptor molecules that are not shown.  AKAP12 also associates with 
the MC1R.  After the MC1R binds its agonist, this leads to activation of the 
receptor and the small Gα protein (GαS).  GαS is responsible for the activation of 
adenyl cyclase, which converts ATP to cAMP.  PKA needs to bind cAMP to 
become active.  Once activated, PKA will phosphorylate specific sites on the 
receptor and the AKAP12 protein.  This phosphorylation will markedly enhance 
the binding of AKAP12 to the receptor.  The enzyme PP2B is responsible for 
dephosphorylation of sites located on the AKAP12 scaffolding protein and the 
MC1R receptor.  This process is critical for AKAP12 ability to mediate the 
resensitization and recycling of the internalized MC1R back to the cell membrane.   
                                  
     There are numerous avenues of the AKAP12 project that need to be explored.  
The regulation of AKAP12 gene expression and function in normal melanocytes 
needs to be determined.  Other research questions include:  What is the identity of 
factor “X”, i.e. the atRA direct target gene that is responsible for induction of 
AKAP12 expression after treatment of melanocytes or responsive melanoma cells 
with atRA?  Second, is there a difference in subcellular location of AKAP12 in 
the melanoma cells compared to the normal human melanocytes?  An altered 
location of AKAP12 in melanoma cells could change the function of this 
scaffolding protein.  Third, how would over-expression of AKAP12 in a cell line 
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such as WM1366 melanoma cells, a rapidly growing, atRA resistant cell line, 
change the physiology of these cells??  I was unable to successfully attain 
overexpression of the AKAP12 gene in these melanoma cells.  The cDNA coding 
for this gene is approximately 5.4kb and is as large as or larger than the 
expression vectors that were used to express the gene in melanoma cells.  The 
very large size of the plasmid impeded its transfection efficiency.  However, an 
adenoviral delivery system may be more successful in achieving high AKAP12 
gene expression.  Fourth, the WM3248 cells express very high basal levels of 
AKAP12 and these levels are further induced by atRA, yet, these cells are only 
moderately responsive to the growth inhibitory effects of atRA.  Why is there a 
strong induction of AKAP12 in cells that are more resistant to atRA-dependent 
growth inhibition??  Last, mutation of sites encoding binding domains for 
important signaling kinases located in the N-terminal region of the protein can 
give insight into how AKAP12 regulates these pathways.  The answers to the 
questions listed above will provide a much deeper insight into the role of 
AKAP12 in melanocyte biology and could uncover therapeutic targets to 
counteract its dysfunction in human melanoma. 
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